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Background: In Orthopaedic surgery the diagnosis, treatment and prevention of 
infection are key to successful patient outcomes, this has led to the increased 
use of antibiotics.  Infection following implant or graft surgery has high levels of 
patient morbidity and associated costs of treatment.  Antibiotic prophylaxis 
coupled with early accurate diagnosis can improve outcomes.  Currently, implant 
related infection is diagnosed using diagnostic algorithms which combine 
numerous blood and tissue investigations, however, there is no single test 
available to rule infection in or out and reliance on clinical judgement is still at 
the forefront.  Novel gene sequencing techniques are coming to the forefront of 
diagnostics across all medical specialties and here I present a pilot study of the 
use of a new sequencing method and diagnostic rationale - looking at the 
patient’s own immune response to identify the presence of implant infection.  
Antibiotic prophylaxis, usually given intravenously at the time of surgery has led 
to a significant reduction in implant infection.  Developing more localised ways 
to administer this prophylaxis led to the introduction of an antibiotic ‘wrap’ - 
whereby tissue graft is wrapped in antibiotic solution prior to insertion.  This 
method has significantly reduced infection rates following graft surgery 
however, it remains unknown if this antibiotic has any adverse molecular or 
biomechanical effect on the graft tissue, an issue this work aims to address.  
Key Findings: Tissue and blood from patients undergoing orthopaedic implant 
related revision surgery was sequenced on a novel immune gene panel.  From 
this, patterns of gene expression were identified in tissue which defined the 
infected from the aseptic control cohort.  Furthermore, the immune gene 
response was able to characterise different time points of infection, identifying 
signatures for acute infection and chronic infection.  Sequencing blood samples 
from the same cohort I was able to establish a gene signature which provided 
genus level bacterial identification, previously only provided following 
microbiology culture.   Vancomycin antibiotic treatment of tendon graft tissue, 
used in anterior cruciate ligament reconstruction, was not associated with an 
increase in apoptotic gene or protein expression.  Furthermore, no consistent 
changes were seen in tendon matrix gene or protein expression.  I did identify a 
consistent trend of reduced levels of inflammatory cytokines following 
vancomycin compared with control conditions.       
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Conclusions: Novel gene sequencing techniques and a ‘switched’ diagnostic 
strategy have shown promise in diagnosing and categorising infection in 
orthopaedic implant surgery.  Antibiotic ‘wrap’ of the hamstring graft in ACL 
surgery may induce a beneficial homeostatic molecular environment, via a 
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 Chapter 1: Introduction 
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1.1 Synovial Joint anatomy 
A joint is formed in the human body where two bones meet.  Synovial joints 
(e.g: hip, knee, shoulder) are the most common type of joint allowing for 
movement of the skeleton.  Although adapted to their specific roles throughout 
the body based on their location and range of movement required, they share 
common characteristics.  At the point where two bones meet or articulate, 
hyaline cartilage covers the articulating surface.  The joint is encased in a 
fibrous capsule that on its inner surface forms the synovial membrane.  This 
membrane acts to filter blood plasma and contains synoviocyte cells that secrete 
proteins, the combination of these proteins and filtered plasma forms synovial 
fluid (Ramachandran, 2006).  Synovial joints are stabilised by ligaments and 
tendons. The key features of a synovial joint are illustrated in Figure 1-1.  
Articular hyaline cartilage creates a smooth lubricated surface for joint 
movement, thereby reducing friction and distributing load across the joint 
(Ramachandran, 2006).  It is composed of chondrocyte cells and extracellular 
matrix (ECM) comprising type II collagen, water and proteins e.g. proteoglycans.  
The arrangement of these cells and ECM are akin to its functions: at the joint 
surface chondrocytes and collagen fibres lie parallel to the joint to resist shear 
forces, while more proximally the cells are rounder and the fibres perpendicular 
to the joint to resist compression Figure 1-2 (Sophia Fox et al., 2009).   
Tendons and ligaments are both examples of dense connective tissue that are 
crucial for the structure and function of joints. Tendons attach muscle to bone 
to permit movement of the skeleton at joints; ligaments attach bone to bone 
providing structural support to the joints of the body.  Tendons and ligaments 
are composed of fibroblast cells and ECM.  Fibroblasts make up 95% of the 
cellular component of the tissues and produce the ECM, comprising collagen, 















Figure 1-1 Schematic diagram of a synovial joint 
A diagram representing the key features of a synovial joint.  The articulating ends of the bones are 
covered with articular cartilage.  A thick fibrous capsule surrounds the joint and provides stability.  
The synovial membrane acts to filter larger molecules from blood and also secrete key proteins to 












Figure 1-2 Schematic diagram of articular cartilage 
A diagram showing the transition from subchondral bone to articular cartilage.  In the deep zone 
chondrocytes are rounder and the type II collagen fibres are tangential to the joint line to 
resist compression.  In the superficial zone cells are flat and collagen fibres parallel to the joint line 
to resist shear.  Above the tidemark, articular cartilage is avascular.  Images created in BioRender, 




Collagen: the most abundant protein in the human body is composed of three 
polypeptide alpha (α) chains, in a triple helix structure, forming tropocollagen.  
In tendon and ligament 85-90% is heterotrimetric Type I collagen, with two-α1 
and one-α2 polypeptide chains.  Tropocollagen synthesis by fibroblasts is then 
assembled into organised fibrils, fibres and fascicles that group together to form 
the whole ligament or tendon.  The orientation of the collagen fibres is dictated 
by the direction of force; in tendons these are uniaxial resulting in parallel 
collagen fibres, in ligaments, there are multi-axial forces resulting in more 
varied cross-connections (Ramachandran, 2006).         
Water: comprises two thirds of the weight of a tendon or ligament and is usually 
bound to negatively charged proteoglycans in the ECM.  It is important for 
lubrication and gliding.    
Glycoproteins: consist of a protein core covalently linked to a carbohydrate 
substrate.  Proteoglycans are the most abundant glycoprotein in tendon and 
ligaments, formed of a core protein with a heavily glycosylated 
glycosaminoglycan (GAG) side chain.  They can be divided into small leucine rich 
proteoglycans (SLRPs), of which the most abundant is decorin which has a 
critical role in collagen fibrillogensis and large aggregating proteoglycans, of 
which the most abundant is aggrecan, which has many negatively charged GAG 
side chains creating a hydrophilic environment important for binding water 
molecules (Thorpe et al., 2013).    
Elastic fibres: formed of a central core of elastin linked to fibrillin type 1 and 2 
polymers.  Elastic fibres have important mechanical functions in energy storage 
and elastic recoil and are aligned with collagen fibres.  The amount of elastic 
fibres varies in tendon and ligament depending on function (Thorpe et al., 
2013). 
1.2 The knee joint and anterior cruciate ligament 
The knee joint is a complex modified synovial hinge joint composed of 
patellofemoral and medial and lateral tibiofemoral articulations. It 
predominantly allows movement in the sagittal plane (flexion and extension), 
but also permits small movements in the coronal plane(varus and valgus) and in 
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the axial plane (internal rotation in flexion and external rotation in extension) 
(Miller et al., 2016). 
The stability of the knee joint is multifactorial and maintained by the shape of 
the tibial and femoral condyles, fibrocartilagenous menisci, extracapsular 
tendoligamentous structures: medial collateral ligament, lateral collateral 
ligament, patella ligament, quadriceps tendon, arcuate and oblique popliteal 
ligaments and intracapsular extra-articular ligaments: anterior and posterior 
cruciate ligament Figure 1-3.  The anterior cruciate ligament (ACL) originates 
from the lateral border of the medial femoral condyle and runs obliquely 
through the intercondylar fossa to a broad insertion at the medial tibial 
eminence (Miller et al., 2016). Transition from ligament to bone is via a 4 zone 
direct fibrocartilagenous enthesis; ligament, cartilage, mineralised cartilage and 
finally cortical bone (Gulotta & Rodeo, 2007). The ACL primarily resists anterior 
displacement of the tibia relative to the femur and is a secondary stabiliser to 
internal rotation when the knee is extended.  It has two distinct fibre bundles, 
an anterior medial bundle that resists anterior tibial translation and posterior 
lateral bundle that resists internal rotation. The blood supply to the ACL comes 
from two primary sources which anastomose; the endoligamentous supply 
formed of small vessels from the medial and lateral geniculate arteries and a 

















Figure 1-3 Knee joint anatomy 
A diagram showing the bones and tendoligamentous anatomy of the knee joint.  Three articulations 
between the femur, tibia and patella form the knee joint: medial and lateral tibiofemoral and patella 
joints.  Medial and lateral fibrocartilagenous menisci increase the congruity of the tibiofemoral 
articulations. Extra articular tenodoligamentous structures are shown in blue and include: MCL= 
medical collateral ligament, LCL= lateral collateral ligament, quadriceps tendon and patella 
ligament.  Intracapsular ligaments shown in red are the anterior and posterior cruciate ligaments.  
Image created in BioRender, adapted from (Miller et al., 2016).
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1.3 ACL injury and reconstruction 
The ACL is one of the most frequently injured ligaments, as a result national 
registries have been set up to analyse trends in ACL rupture and repair; they 
estimate the incidence of ACL rupture to be 34 per 100,000 population 
(Renstrom et al., 2008).  Injury can lead to knee joint instability, pain, reduced 
functional performance in athletes and can accelerate degenerative changes to 
the soft tissues in the knee leading to osteoarthritis.  ACL injuries are caused by 
acute contact knee trauma and increasingly, non-contact pivot/twisting knee 
injuries.  The latter group can be affected by age, gender, genetics and body 
weight.  ACL injury rate is reported to be higher in female athletes compared 
with male athletes; differences in elastin and protein content (Little et al., 
2014), size of the ACL and the intercondylar notch it passes through, lower limb 
alignment and hormone differences are all believed to play a part (Renstrom et 
al., 2008).  Age associated degeneration of the ACL shows disordered collagen 
fibres and increases in cell number and GAG protein accumulation, changes that 
are understood to play a role in non-contact pathogenesis of ACL rupture 
(Hasegawa et al., 2013).  Following rupture, ligament healing occurs via a 3-
phase pathway of inflammation, proliferation & repair and remodelling. 
Inflammation: immune cells including platelets, monocytes, macrophages and 
neutrophils, migrate to the site of injury forming a haemostatic clot and begin to 
remove tissue debris by phagocytosis.  There is an increase in water, GAG 
content and Type III collagen in the ligament tissue (Lin et al., 2004).   
Proliferation & Repair: ligament tissue has a scar like appearance with a dense 
network of blood vessels. There remains a high level of Type III collagen, water 
and GAG proteins (Lin et al., 2004).  
Remodelling: begins around 6-8 weeks after injury.  There is a reduction in 
cellularity of the tissue, along with water and GAG content.  Type III collagen is 
replaced with Type I collagen, which begins to align along the axis of force.  The 
repaired tissue does not regain the mechanical properties pre-rupture due to 
residual increased cellularity and more disorganised collagen fibre arrangement 
(Lin et al., 2004).  
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Repair of the intra-articular ACL is poor, limited by its avascular nature which 
reduces inflammatory cell migration, and, the presence of synovial fluid (Murray 
et al., 2000).  Studies have shown that the torn ligament ends retract and are 
covered by synovial membrane preventing repair(Murray et al., 2000).   
Ligament reconstruction is the current gold standard of surgical treatment 
following ACL rupture.  Tissue is taken from the patient’s hamstring or patella 
tendon, or donor tissue is used and implanted through bone tunnels in the femur 
and tibia, to replicate the normal anatomical position of the ACL.  Surgical 
reconstruction has superior results compared with conservative management in 
active patients with regards to return of pre-injury sporting activity (Monk et al., 
2016); Using the patient’s own tissue – ‘autograft’ compared with donor tissue 
‘allograft’ is also associated with a lower re-rupture and revision rate, a zero 
risk of disease transmission and no immune mediated reaction to foreign tissue 
(Gulotta & Rodeo, 2007; Maletis et al., 2013; Marrale et al., 2007).  Previous 
research has evaluated many aspects of the surgery, anatomical graft placement 
is now accepted as good practice, but other aspects of surgery including graft 
choice and fixation device show no superiority, with a trend now towards a more 
personalised surgery (Haddad, 2014).  The limiting factor in reconstruction is the 
biology of graft healing which describes the process of graft integration into the 
bone tunnels in the femur and tibia.  This process occurs with hamstring and 
patella tendon grafts, the latter of which has bone blocks at either end of the 
tendon graft, however, a portion of the tendon will remain in the tunnel.  The 
tendon graft heals to bone initially with fibrocartilaginous scar tissue.  The 
collagen fibres in this scar then align perpendicular to bone, in a similar way to 
Sharpey’s fibres present at indirect tendon-bone attachments (Gulotta & Rodeo, 
2007).  The body of the tendon graft undergoes ‘ligamentisation’ – a process that 
can take up to 3 years, comprising avascular necrosis, cellular re-population, 
revascularisation and fibroblast metaplasia, resulting in a graft that is 
histologically similar to a native ACL (Deehan & Cawston, 2005; Gulotta & 
Rodeo, 2007).   
1.4 Infection following ACL reconstruction 
Post-operative infection following anterior cruciate ligament reconstruction 
(ACLR) is an uncommon but serious complication.  Is has the potential to damage 
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the ACL graft and destroy articular cartilage leading to septic arthritis.  The 
prevalence ranges from 0.14-1.8% (Burks et al., 2003a; Indelli et al., 2002; 
Torres-Claramunt et al., 2013).  A large systematic review evaluated 14 studies 
assessing infection following ACLR; reporting a rate of 0.5%, based on 121 cases 
of infection out of 22,836 ACL surgery’s.  Increased risk of infection following 
ACLR is seen when additional procedures are performed, for example, meniscal 
repair, or in revision surgery (Kim et al., 2014).  This may be due to increased 
operating times, larger surgical incisions or more ‘foreign’ suture material in the 
knee joint.  As the condition is less common, there have been varying opinions 
and protocols for treatment.  Synovial fluid aspiration to confirm the diagnosis 
along with administration of intravenous antibiotics and joint lavage are key.  
Choice and duration of antibiotics are guided by microbiology culture results, 
with the majority of infections caused by a Staphylococcal organism (Kim et al., 
2014).  The issue lies with how to treat the graft, either to retain it or remove it 
at first wash out.  Published literature is available supporting both arguments 
(Burks et al., 2003b; Michael E. Hantes et al., 2017; Matava et al., 1998).  
Retention or removal of the graft may ultimately depend on patient, graft and 
microbial factors, with higher virulent organisms and allograft reconstruction 
associated with poorer outcomes (Michael E. Hantes et al., 2017; Matava et al., 
1998).       
1.5 Vancomycin wrap and ACL surgery  
Current research in the field of ACL surgery is directed towards the use of 
biological agents to improve graft integration, reduce re-rupture rates and 
crucially, reduce post-operative infection rates (Hexter, Thangarajah, et al., 
2018; Vertullo et al., 2012).  In 2012 the vancomycin wrap was introduced; this 
involves wrapping the ACL graft in a sterile swab pre-soaked in 5mg/ml of 
vancomycin antibiotic solution whilst the graft bed and bone tunnels are 
prepared.  The data from this initial study showed a significant reduction in 
post-operative infection rates in the vancomycin wrap treated group, N=870, 
infection rate 0% vs pre-operative antibiotics alone N=285, infection rate 1.4% 
(Vertullo et al., 2012).  Results from this study have been replicated by other 
research groups, showing that vancomycin treatment of the ACL graft 
significantly reduces infection rates (Naendrup et al., 2019; Offerhaus et al., 
2019; Pérez-Prieto et al., 2016; Phegan et al., 2016).  Vancomycin is a 
23 
 
glycopeptide antibiotic initially developed to treat Methicillin resistant 
staphylococcus aureus (MRSA) and coagulase negative staphylococcus aureus.  It 
is used in a number of specialities, including urology, cardiothoracic and 
orthopaedic surgery, either topically on wounds on in solution to immerse or 
wrap implants prior to surgery, reporting significant reductions in infection 
(Dhabuwala, 2010; Tarakji et al., 2016; Vander Salm et al., 1989).  In 
cardiothoracic surgery, topical vancomycin powder is applied to sternotomy 
wounds following a seminal paper in 1989 and more recently implantable cardiac 
electronic devices are enveloped in a degradable antimicrobial sleeve (Tarakji et 
al., 2016; Vander Salm et al., 1989). In orthopaedic surgery, vancomycin powder 
is reconstituted in bone cement for routine arthroplasty and used as intravenous 
solution to treated prosthetic joint infection (Nowinski et al., 2012). A recent 
paper has shown that topical vancomycin powder significantly reduces both 
superficial and deep surgical site infection rates when applied to spinal surgery 
wounds, compared with a control group with no intrawound treatment (Lemans 
et al., 2019). The molecular effects of vancomycin on human and animal peri-
articular tissues, including tendon has a limited evidence base. Porcine 
chondrocyte death was significantly increased after exposure to vancomycin at 
doses of 5mg/ml or higher (Shaw et al., 2018).  Human in vitro studies have 
shown vancomycin toxicity to chondrocyte and osteoblast like cells, via a 
reduction in cell DNA, at doses of 250µg/ml and 125µg/ml for osteoblast and 
chondrocytes respectively, following 48hours of treatment (Antoci et al., 2007).  
Two further studies have concluded that vancomycin is not toxic at doses up to 
16µg/ml for 36 hours in an ex vivo chondrocyte model (Dogan et al., 2016) and 
up to 1000µg/ml for 72 hours in an in vitro osteoblast model (Edin et al., 1996).  
Porcine tendon models show that vancomycin is effective at eliminating 
bacterial contamination at 5mg/ml after 20 minutes of soaking, and has no 
effect on the biomechanical properties at doses up to 10mg/ml(Schüttler et al., 
2019).  Bovine studies have demonstrated that tendon can act as a reservoir for 
vancomycin, releasing the antibiotic for up to 24 hours into the joint, changing a 
source of infection, into an intra-articular prophylactic vehicle (Grayson et al., 
2011).   
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1.6 Tendon work aims 
The clinical data shows that vancomycin, when used topically to treat the ACL 
graft, significantly reduces post-operative infection rates.  This has been shown 
in animal studies (Schüttler et al., 2019) and in a number of human clinical trials 
(Offerhaus et al., 2019; Pérez-Prieto et al., 2016; Vertullo et al., 2012).  Based 
on these results, the vancomycin wrap is currently employed in many clinical 
settings.  However, studies looking at vancomycin toxicity in periarticular tissue 
give varying ranges for a safe dose regime and do not include human tendon 
tissue.  It remains unclear if pre-treatment with vancomycin has any detrimental 
molecular or structural effects on the tendon graft, a gap in the current 
literature which this study aims to address.   
1.7 Osteoarthritis and Total Joint Replacement  
Osteoarthritis (OA) is the most common form of degenerative joint disease.  It 
can be classified as primary OA, with risk factors including increasing age, 
female gender, obesity, and repetitive joint loading or secondary OA, which 
occurs due to an identifiable cause e.g.: trauma, joint surgery or developmental 
abnormality.  The pathophysiology of OA involves the whole joint but begins 
with damage or fibrillations in the articular cartilage.  This exposes the 
underlying subchondral bone, disrupts the osteochondral junction allowing 
pathological vascular and neural invasion.  The ECM, chondrocyte and collagen 
network of the cartilage, shown as normal in Figure 1-2, is disrupted; 
proteinases – enzymes that break down collagen and ECM are increased, and 
there is accelerated chondrocyte cell death.  Subsequent changes to subchondral 
bone, including reduced bone mineral density alters the mechanical properties 
of the joint further increasing the cartilage damage and leads to bone cyst 
formation.  Finally, the proteinases released by damaged chondrocytes interact 
with the synovium, releasing further inflammatory cytokines including IL-1, IL-6 
and IL-15.  Treatment options include supportive measures: pain relief, activity 
modification and weight loss, or surgery, either to re-align and re-stabilise the 




National joint registry (NJR) data in England show that total hip replacements 
(THR’s) and total knee replacements (TKR’s) are the most common arthroplasty 
surgeries performed (NJR Editorial Board, 2019).  The goal of arthroplasty 
surgery is to relieve the pain caused by ‘bone on bone’ articulation at the joint, 
and replace this with a biomaterial implant, restoring joint function and quality 
of life.  Using THR as an example, the modern low friction design of which is 
accredited to Sir John Charnley in 1962, consists of a femoral stem, head and 
acetabular cup Figure 1-4 (Knight et al., 2011).  The femoral stem is made from 
a metal alloy, commonly stainless steel. It can be implanted with or without 
bone cement, known as polymethymethacrylate that acts as a grout between 
bone and implant.  Uncemented implants are coated with hydroxyapatite, the 
mineral form of bone, which promotes bone in growth into pores in the implant 
to create a stable construct (Knight et al., 2011; Ramachandran, 2006).  The 
head of the femur is replaced with a cobalt chromium or ceramic ball, with its 
size corresponding to the implanted acetabular cup.  The hip socket or 
acetabulum is formed from the fusion of three bones of the pelvis, the ilium, 
ischium and pubis, and is lined by articular cartilage.  Any remaining cartilage is 
removed by reaming during surgery and a new cup implanted, either with bone 
cement or coated with hydroxyapatite to allow for bone in growth as with the 
femoral stem.  Uncemented cups are made from metal alloys and require a liner 
to articular with the femoral head, which is either ultra-high molecular weight 
polyethylene (UHMWPE) or ceramic.  Cemented cups are UHMPE and can 
articulate directly with the femoral head (Knight et al., 2011).  Whilst the basics 
of hip replacement surgery have remained similar since their introduction, there 
have been vast advances in biomaterial engineering to improve the function and 
longevity of the implants.  Implants are available for ankle, knee, shoulder, 
elbow, wrist and hand joint replacements and utilise the principles described 
here for THR.  With advances in surgical technique and implant development, 
NJR data shows that 15 years following surgery, approximately 92% of THRs and 
93% of TKR’s are still functional (NJR Editorial Board, 2019).  Through a series of 
questionnaires assessing function, pain and quality of life, patients are able to 
report their outcomes following arthroplasty surgery, known as Patient Reported 
Outcome Measures (PROMS) data, which has been collected by NHS England since 
2009.  For the 2018-2019 period, 97% of patients who underwent a THR and 94% 
of those undergoing a TKR reported improvements in their overall heath 
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following surgery (NHS Digital & Analytical Team PROMS, 2020).  Despite the 
documented success of arthroplasty surgery, there are complications that can 






Figure 1-4 A schematic diagram of a total hip replacement 
(A) Normal anatomy of the hip joint, a synovial joint, formed by the head of the femur articulating 
with the acetabulum.  The femoral head and the acetabulum are covered with articular cartilage, 
shown in grey.  The red lines indicate the bone cuts and areas of reaming to remove any remaining 
articular cartilage.  (B) Implants used in a total hip replacement.  The femoral stem is placed down 
the femur and is stabilised with bone cement or has a coating of Hydroxyapatite to stimulate bone 
growth onto the stem. The acetabular implant shown here is metal, coated with hydroxyapatite to 
stimulate bone growth to fix the implant in the acetabulum, with a liner, shown in blue, to articulate 
with the femoral head.  Image created in BioRender.
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1.8 Prosthetic Joint Infection and Biofilm 
A surgical prosthesis or implant is susceptible to infection from three primary 
sources.  The primary pathway is understood to be contamination of the implant 
or seeding of microorganisms onto the implant at the time of surgery, as data 
shows that nearly 50% of infections occur within the first year (Tande & Patel, 
2014).  Animal models have shown that when a prosthesis is implanted, a 
significantly smaller amount of bacteria is needed to establish infection versus a 
model with no implant, suggesting the implant reduces the immune response to 
bacteria thereby allowing immune evasion and survival (Southwood et al., 1985).  
Secondly, contiguous spread from a local source, including superficial surgical 
wound infection to involve the implant.  Later, this can include disruption to 
local tissues cases by trauma, surgery or superficial infection such as cellulitis.  
Thirdly, a prosthesis can become infected at any point during its lifetime via 
haematogenous spread and seeding of bacteria onto the implant from a distant 
site (Tande & Patel, 2014).Therefore a complex underlying interaction between 
the immune response, invading microorganism and implant; results in a unique 
environment and the subsequent development of a biofilm on the implant.  
Biofilm consists of microorganisms, either monomicrobial or polymicrobial, 
embedded in an ECM which consists of proteins, polysaccharides and 
extracellular DNA (eDNA).  The formation and development of biofilm can be 
described in four stages: 
Attachment: bacterial attachment can occur via two routes, reversible 
electrostatic forces and irreversible binding via bacterial cell wall proteins 
(Gbejuade et al., 2015).  Immediately following implantation, the prosthesis is 
coated with blood and interstitial fluid that contains host proteins including 
fibrinogen, collagen and fibronectin.  Staphylococcus aureus (S.aureus) is the 
most common causative organism is PJI and is therefore the bacteria most 
extensively studied.  S.aureus has several microbial surface components 
recognising adhesive matrix molecules (MSCRAMs) and secretable expanded 
repertoire adhesive molecules (SERAMs) that facilitate adhesion to host proteins 
including collagen-binding adhesins that bind collagen and fibronectin binding 
proteins that bind to fibronectin (Arciola et al., 2018).  The concept of ‘race to 
the surface’ describes the competition between bacteria and host cells, as to 
which occupies the implant surface first.  If the bacteria is first, integration of 
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the implant with bone may not occur and biofilm infection may form (Arciola et 
al., 2018)  
Proliferation: once the bacteria are attached to the implant surface they can 
begin proliferation, production of ECM and formation of cell to cell adhesion 
bonds (Gbejuade et al., 2015). 
Maturation: growth and regulation of the biofilm is coordinated by a unique 
bacterial signalling pathway of quorum sensing, controlled by the agrBDCA 
genes. This pathway regulates bacterial growth and response to stress signals, 
including hypoxia and cell density (Arciola et al., 2018; Gbejuade et al., 2015).  
A number of bacteria in the biofilm undergo programmed cell death or apoptosis 
in order to release eDNA into the ECM which allows resistance genes to be 
transferred to other bacteria within the biofilm.  
Detachment: bacteria can disperse from the biofilm and spread via the 
bloodstream which may lead to systemic infection.  This process is coordinated 
by the agr quorum sensing genes that signal the production of enzymes to break 
down bonds within the biofilm ECM, allowing bacteria to disperse (Arciola et al., 
2018; Gbejuade et al., 2015). 
The initial immune response treats the implant as a foreign body. As noted 
earlier, on contact with blood and interstitial fluid, it is coated with host 
proteins, also known as provisional matrix, which can act as attachments for 
bacteria but also initiate the complement and coagulation cascades.  This 
triggers a release of cytokines and chemo-attractants for cells involved in the 
innate immune response Table 1-1.  Neutrophils are the first cells to respond.  
These are polymorphonuclear leukocytes, also known as granulocytes that have 
numerous roles: phagocytosis of mirco-organisms and cell debris, release of 
antimicrobial peptides known as defensins, the production of neutrophil 
extracellular traps and NETosis – whereby a neutrophil releases a web of histones 
and granules to trap microorganisms, and the production of chemokine’s to 
recruit other immune cells (Selders et al., 2017).  The inflammatory response 
evolves from acute to chronic with the arrival of monocytes and their maturation 
to macrophages, which promote proliferation of fibroblasts and endothelial cells 
leading to granulation, fibrous tissue and the formation of multinucleated giant 
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Table 1-1 Components of the innate immune system 
Innate Immune system 
Physical barrier Skin, mucosal epithelium  
Circulating proteins 
Complement 












Natural Killer cell, mast 




cells (Anderson, 2001).  The pathway of immune response to the implant is 
affected by a number of factors including the bearing surfaces of the implant 
and the volume of wear particles produced overtime, with a lower immune 
repose noted when the foreign material remains in ‘bulk’ form (Gibon et al., 
2017).  Despite this, a common pathway of granulocyte activation, chronic 
inflammation and giant cell formation is summarised in Figure 1-5.  
The purpose of immune cell migration is to promote phagocytosis to clear micro-
organisms from the tissue implant interface, however, due to the size and 
properties of orthopaedic implants, this is not possible.  This leads to a 
phenomenon called ‘frustrated phagocytosis’ characterised by partial 
degranulation of immune cells, increased oxygen free radial production leading 
to cell apoptosis and degradation of defensins (neutrophil antimicrobial 
peptides) (Zimmerli & Sendi, 2011).  
Furthermore, biofilm microorganisms have multiple methods by which they can 
evade the host immune response. Phagocytes can be physically excluded due to 
their size from micropores on the surface of the implant, which can instead be 
colonised by bacteria (Arciola et al., 2018).  S.aureus has an array of defence 
mechanisms against the immune response, including inhibiting opsonisation, 
producing enzymes to breakdown neutrophil extracellular traps and releasing 
leucocyte toxins (Arciola et al., 2018).  Small colony variants (SCV’s) are a 
subpopulation of biofilm bacteria that can invade host cells, including 
osteoblasts and non-immune cells, evading detection and elimination by the 
immune system and antimicrobial therapies.  They are able to re-initiate 
infection following completion of antibiotic therapy (Arciola et al., 2018; 





Figure 1-5 Biological response to an orthopaedic implant 
The implant is coated with host proteins, ‘provisional matrix’ which activates the coagulation and 
complement cascades, attracting phagocytes.  The cells are unable to phagocytose the implant 
and undergo partial degranulation and increased free radial production leading to frustrated 
phagocytosis.  Bacteria have specific receptors that bind to host proteins in the provisional matrix 
on the implant, coupled with inefficient phagocytosis, this can lead to biofilm formation.  Wear 
particles are produced by the implant which activate macrophages either by phagocytosis or 
through surface toll-like receptors.  Activated macrophages assume a pro-inflammatory phenotype, 
increase the release of cytokines to recruit more macrophages, differentiated into osteoclasts to 
resorb bone or fuse to generate multi-nucleated giant cells.  Osteoclasts can lead to bone 
resorption and subsequent loosening of the implant; MGC’s lead to granuloma formation. MΦ= 
macrophage, TNFα = tumour necrosis factor alpha, IL = interleukin, MCG’s – Multinucleated Giant 
Cells.  Image created in BioRender, adapted from (Anderson, 2001; Gibon et al., 2017)  
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Recent work investigating biofilms has suggested an alternative pathway 
describing chronic infection of implants. These studies report an alternative 
activation pathway involving macrophages; instead of pro-inflammatory 
cytokines (IL-1, IL-6, IFNg), anti-inflammatory cytokines (IL-10 ,IL-4) weaken the 
microbicidal response leading to pro-fibrotic changes and chronic infection 
(Gries & Kielian, 2017).  Utilising mouse models of PJI and human PJI tissue 
samples, an altered immune cell environment was described, with an increased 
number of immature monocyte and macrophage pre-cursor cells namely myeloid 
derived suppresser cells and a reduction in T cell number (C. E. Heim et al., 
2014; Cortney E. Heim et al., 2018; Cortney E. Heim, Vidlak, & Kielian, 2015).  
Through a more detailed understanding of the immune cell reaction and 
cytokines involved in the development and persistence of biofilm, it is hoped 
that molecular targets can be developed to aid with clinical diagnosis and 
management of PJI (Gries & Kielian, 2017).    
1.9 Epidemiology of prosthetic joint infection 
The NJR has been collecting data on all arthroplasty surgeries in England and 
Wales since 2003.  Its database estimates the prevalence of prosthetic joint 
infection (PJI) to be between 0.8-2%, based on a recording of over 2,500,000 
surgeries (NJR Editorial Board, 2019).  The Scottish arthroplasty project, 
founded in 2001, produces an annual report looking at arthroplasty surgery in 
Scotland, it includes infection rates occurring within 1 year of surgery.  In 2018 
these figures were 0.9% for THR and 0.8% for TKR (Scottish arthroplasty project 
steering group, 2020).  Available registry data suggests that approximately half 
of PJI’s occur within 2 years of the primary surgery (NJR Editorial Board, 2019; 
Ong et al., 2009).  However, up to 25% of patients can develop symptoms of 
primary infection up to 10 years following initial surgery (Lamagni, 2014; Ong et 
al., 2009).  This can lead to a time lag and an under appreciation of the burden 
of PJI, given the large increase in arthroplasty in the last 5-10 years (NJR 
Editorial Board, 2019).  Conflicting reports suggest that the absolute incidence 
of PJI is increasing.  Data from the Nordic Arthroplasty register, a consolidation 
of data from 4 Nordic countries’, investigated 432,168 THR’s, including 2778 
revision surgeries for infection. They reported an increase in the incidence of PJI 
in the years 2005-2009 calculated at 0.71% compared with 0.46% in 1995-1999.  
This increase was exclusively within the 1st year post primary surgery and was 
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not associated with an increase in incidence of known PJI risk factors (Dale et 
al., 2012).  This finding is not supported by data from America, where a smaller 
sample size of 7367 arthroplasty surgeries reported static rates in PJI incidence 
over  a 10-year follow up (Tsaras et al., 2012).  Reasons for this may be an inter 
play between increased co-morbidities within the operative population, 
improved infection prevention measures and implant design (Tsaras et al., 
2012).   Furthermore, national joint registries may underestimate the prevalence 
of PJI, as microbiology results to stratify a case as infected are not available at 
the time of data entry on to the register.  A study investigating this 
underreporting evaluated the Danish Hip Arthroplasty register, capturing 32,896 
THR’s, of which 1546 required revision.  They found that relying on the registry 
to document a case as infected gave 1- and 5-year cumulative infection rates of 
0.5% and 0.64% respectively.  Utilising their algorithm, which drew on national 
clinical patient data including blood and microbiology results and pharmacy 
prescriptions up scaled this estimate to 1 and 5 year cumulative infection rates 
of 0.86% and 1.03% respectively, 40% higher than the registry data alone 
(Gundtoft et al., 2015). 
The volume of arthroplasty surgery has increased over the last few years.  The 
UK NJR shows that 25% of the total database entries were recorded in the years 
2016 to 2018 (NJR Editorial Board, 2019).  Despite the conflicts regarding 
increased incidence, and the balance of patient co-morbidities, surgical 
technique and implant design, we can predict that the absolute number of PJI 
cases will rise.     
1.10 Risk factors for Prosthetic joint infection  
Factors known to increase the risk of PJI include; multiple underlying co-
morbidities, particularly diabetes, liver or renal disease, increased BMI 
>30kg/m2, increased surgical operating time, revision surgery and male gender 
(Alamanda & Springer, 2019; Namba et al., 2013; NJR Editorial Board, 2019; Ong 
et al., 2009).  Large registry data sets can stratify these risks further, for 
example, liver disease as a risk factor reaches significance >24 months after 
primary surgery whereas diabetes is a risk factor for early infection (NJR 
Editorial Board, 2019).  Infection is the 4th most common reason for primary THR 
revision in UK joint registry data however, it becomes the leading cause for re-
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revision surgery (NJR Editorial Board, 2019) which is believed to be due to 
poorer quality soft tissues, longer operating times and potentially undiagnosed 
low-grade infection at the time of revision.  Male gender has been identified in a 
number of studies as being a factor of increased infection risk, although the 
biological reason for this is unexplained (Dale et al., 2012; Ong et al., 2009).  
Evidence suggests that implant bearing surface may play a role in infection 
rates, with ceramic surfaces associated with lower rates (Madanat et al., 2018).  
However, ceramics are used in younger patients, therefore this may be a 
confounding factor in these results.  On the other hand, a large meta-analysis 
comparing ceramic, metal and UHMPWE identified no difference in infection 
rates (Hexter, Hislop, et al., 2018).  Increasing age has not consistently been 
shown to be associated with increasing infection.  One study, using UK NJR data 
looked at 623,253 THR’s and reported an increased risk of infection with age >70 
(NJR Editorial Board, 2019).  However, a report of 39,929 patients found age to 
be non-significant in the overall cohort for developing infection (Ong et al., 
2009).  A large meta-analysis reviewed 104 studies encompassing over 640,000 
total elbow and total shoulder replacements and found that age >75 years was 
associated with a lower risk of infection vs <75 years.  One study in this meta-
analysis reported high levels of cutibabterium acnes (C.acnes) in younger males 
which may have affected these results (Kunutsor et al., 2020). 
1.11 Diagnosis of PJI and Consensus definition 
Prior to 2011, the diagnosis of PJI was based on clinical history, blood 
inflammatory markers, tissue and synovial fluid culture, and histology.  Without 
a standardised definition, the interpretation of these results was clinician based.  
The predominate pathogen seen on culture is S.aureus, however, there is a high 
number of poly-microbial infections and organisms of lower virulence such as 
Proteus species or C.acnes (Lamagni, 2014).  This in part could account for the 
varying clinical picture from an acutely hot swollen painful joint to indolent 
increase in pain and stiffness, making diagnosis challenging.  Furthermore, 
although the majority of infections occur acutely following surgery, a significant 
proportion present between 2-10 years post-operatively (Lamagni, 2014), see 
section 1.9.  The varying clinical picture and lack of standardised definitions can 
lead to wide variation in clinical outcomes, making clinical research in this area 
inconsistent and therefore difficult to interpret. 
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In 2011 a standardised definition of PJI was formulated by the musculoskeletal 
infection society (MSIS), based on consensus opinion and review of the available 
literature, as summarised in Table 1-2.  An international consensus group 
(International Consensus on Musculoskeletal Infection, ICM) updated the 
definition in 2013, modifying the minor diagnostic criteria to include leucocyte 
esterase, Table 1-3, and a sub-classification of acute and chronic infection Table 
1-4.  With the introduction of debridement, antibiotics with implant retention 
surgery (DAIR) and single staged revisions, separating this infected cohort 
became relevant to treatment decisions. 
A standardised definition of PJI has allowed research in the field to expand 
resulting in several new biomarkers for infection being proposed.  A number of 
these biomarkers are included in the 2018 ICM consensus update to the 
definition of PJI, which has adopted an algorithm approach Table 1-5.  Aiding 
pre-operative surgical decision-making, a scoring system assesses the likelihood 
of an implant being infected.  More recently, the European Bone and Joint 
Infection Society (EBJIS) supported by the MSIS have developed a 3-step 
guideline to diagnose PJI based on clinical history, examination findings and 
available diagnostic tests.  If results from all tests come back negative then it is 
deemed ‘infection unlikely’.  If two of the chosen parameters are positive, then 
‘Infection Likely’ is concluded.  Key diagnostic tests with the highest reported 
sensitivities from published literature diagnose ‘Infection confirmed’ if one 




Table 1-2 2011 MSIS PJI criteria 
The criteria proposed to diagnose PJI.  ESR = Erythrocyte sedimentation rate, CRP = C reactive 
protein, WCC = white cell count, HPF = High powered field.  CRP, WCC and synovial WCC values 
are included in the definition based on previous research.  Table adapted from (Javad Parvizi et al., 
2011). 
Definite PJI exists when 
1. A sinus tract communicates with the prosthesis    
OR 
2. The same pathogen is isolated by culture from two separate tissue or 
fluid samples from the prosthesis     OR 
3. Four of the following six criteria are met: 
a Raised ESR (>30mm/hour) and CRP (>10mg/L) 
b Elevated synovial WCC (>3000 cells/µL) 
c Elevated synovial neutrophil % (>80%) 
d Pathogen isolated by culture from one tissue or fluid sample 
e Presence of pus in the joint 
f Histology tissue analysis reveals >5 neutrophils per HPF in 5 HPF’s 
 
Table 1-3 2013 update to MSIS PJI criteria 
The updated diagnostic criteria included Leucocyte esterase.  Table adapted from (Javad Parvizi & 
Gehrke, 2014). 
Definite PJI exists when 
Major criteria 
A sinus tract communicates with the prosthesis    
OR 
The same pathogen is isolated by culture from two separate 
tissue or fluid samples from the prosthesis 
Minor criteria 
3 out of 5 
Raised ESR (>30mm/hour) and CRP (>10mg/L) 
Elevated synovial WCC or Leucocyte esterase strip (++) 
Elevated synovial neutrophil % (>80%) 
Pathogen isolated by culture from one tissue or fluid sample 






Table 1-4 Acute and Chronic PJI criteria 
Minor criteria thresholds for defining acute and chronic PJI.  Table adapted from (Javad Parvizi & 
Gehrke, 2014). 
Criteria Acute <90 days Chronic >90 days 
ESR (mm/hr) N/A 30 
CRP (mg/L) 100 10 




Leucocyte esterase + or ++ + or ++ 
Histology (neutrophils /HPW) >5 >5 
 
Table 1-5 2018 PJI diagnostic algorithm 
Most recent update to the PJI diagnostic criteria including new biomarkers.  Table adapted from 
(Javad Parvizi et al., 2018).   
 
  
 Sample  Test Score Decision 
Major Criteria 
Two Positive cultures same organism 










2-5 Possibly infected 











PMN >80% 2 
Elevated synovial 
CRP >6.9 mg/L 1 
Intraoperative 
diagnosis 
Preoperative score - ≥6 Infected 
4-5 Inconclusive 
≤3 Not infected 
Positive histology 3 
Positive Purulence 3 
Single positive culture 2 
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1.11.1 Microbiology and histology analysis 
Microbiological analysis of tissue from a suspected infected prosthesis forms the 
backbone of previous and current guidelines for diagnosing PJI.  Two identical 
organisms cultured from intra-operative tissue samples confirm that an implant 
is infected (McNally et al., 2020; Javad Parvizi et al., 2018).  To optimise 
microbiological diagnosis, current research suggests that multiple samples are 
taken from different areas of the joint using separate instruments for each 
sample.   Recommendations are for five tissue samples, however, a more recent 
study has suggested four samples, utilising three different culture media’s is 
sufficient, has high levels of concordance (up to 99.7%) and can reduce costs 
(Atkins et al., 1998; Bémer et al., 2016).  Multiple samples increase sensitivity 
and specificity by distinguishing contaminants from infecting organisms.  
Microbiological cultures are incubated for a minimum of 5 to 14 days (Bémer et 
al., 2016; Drago & De Vecchi Elena, 2017) .  The location of the tissue samples 
can also affect the culture outcome, suggesting that there is a spatial aspect to 
bacterial clusters (Walker et al., 2020).  The other major criteria is the 
formation of a sinus between skin and implant, however, swabs or samples from 
the sinus are often contaminated with skin organisms and are not utilised for 
diagnosis.   
Culture of synovial fluid can be performed pre-operatively to aid PJI diagnosis. 
Evaluated in a series of 145 revision TKR’s, 40 of which were classified as PJI, 
synovial fluid culture had a sensitivity and specificity of 72.5% and 95.2% 
respectively (Fink et al., 2008).  In this study, synovial fluid culture was found to 
be inferior to tissue culture.  A large meta-analysis of 34 studies that evaluated 
pre-operative synovial fluid culture reported pooled sensitivity and specificity 
values of 76% and 95% respectively (Qu et al., 2013).  Aspiration form TKR’s was 
found to have higher diagnostic accuracy that THR, this may reflect the 
technical challenges and potential for contamination with hip aspiration.  In 
more recent studies synovial fluid culture has been used as a comparison for 
more modern molecular techniques.  In these studies sensitivity and specificity 
results concur with the values above, 66.3-72.2% and 96-96.9% respectively 
(Cazanave et al., 2013; Ryu et al., 2014).  Synovial fluid, if it can be obtained, 
remains a useful test given its specificity and versatility Table 1-5.    
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Synovial fluid and tissues samples can be analysed by histology techniques to 
give pre, intra and post-operative results regarding PJI.  Synovial fluid aspirated 
pre-operatively can be assessed under high-powered microscope for the 
presence of white cells (WCC) and the percentage of polymorphonuclear cells 
(%PMN). The current recommended cut off values are >3000 WCC and >80% PMN 
(Bori, 2018; McNally et al., 2020).  Tissues may be analysed by frozen section to 
give intra-operative and by paraffin section to give definitive post-operative 
number of neutrophils per high powered field in 5 separate fields, with the 
current cut off being >5. Histology techniques can also be limited in coagulase 
negative staphylococcus infections (Bori, 2018). 
The formation of biofilm on an implant can give rise to issues not only with 
eradication but also detection of the pathogen on tissues culture.  Sonication, a 
method that uses sound energy to disrupt this biofilm membrane on the implant 
is now increasingly used.  In a comparative study of 331 patients, 79 with 
confirmed PJI, sonicated fluid had a sensitivity of 78% and specificity of 98.9%, 
compared with standard tissue culture 60.8% and 99.2% (Trampuz et al., 2007).  
These finding have been replicated in a number of further studies showing that 
sonicate fluid culture had increased sensitivity compared with tissue and 
synovial fluid culture (Cazanave et al., 2013) with equivocal specificity 
(Cazanave et al., 2013; Portillo et al., 2012).  Sonication is a potential method 
to improve standard microbiological culture and molecular techniques, 
particularly in a culture negative or chronic infection scenario and the technique 
is included in the EBJIS diagnostic guideline (McNally et al., 2020).  
1.11.2 Molecular methods 
The clinical challenge of receiving a negative culture result in suspected PJI, 
where other diagnostic markers point towards infection but no organism can be 
identified, has demanded the use of more advanced molecular methods.  
Although not included in the 2018 PJI definition update, or 2020 EBJIS 
guidelines, in clinical practice if traditional and extended tissue culture methods 
report no bacterial growth, samples are sent for analysis using molecular 
techniques.  The results can therefore be considered as an extension of 
microbiology culture.   Molecular polymerase chain reaction (PCR) techniques 
can be used in a number of ways to diagnose PJI.  Specific PCR, whereby primers 
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for specific microorganisms or genes are used to detect their presence, or Broad 
PCR, which identifies a highly conserved region of ribosomal RNA common to 
almost all bacterial species and amplifies it to detect the presence of 
microorganisms (Drago and De Vecchi Elena, 2017). Current clinical practice 
utilises 16s rRNA PCR, the studies that have evaluated this technique and 
compared it with conventional tissue and synovial fluid culture techniques are 
summarised in Table 1-6.  The reported sensitivity from the 13 studies ranged 
from 64.3% - 100%, similarly with specificity 74%-100%.  This method has been 
evaluated on a range of biological samples: tissue, synovial fluid aspirate and 
sonicate fluid, and it allows bacterial RNA detection in samples even if prior 
antibiotics have been administered.  Despite these advantages it is not a first 
line investigation for PJI due to limitations of cost, laboratory technique and the 




Table 1-6 Studies evaluating broad 16s rRNA PCR in PJI 
 
 





















Aseptic 5 Sonicate fluid 
RT-qPCR 16s 
rRNA Not reported Not reported 
Fenollar 
2009 
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Aseptic 50 Synovial fluid 
16s rRNA RT 
qPCR 64.3% 100% 
Marin 2012 
PJI 40 
Aseptic 82 Tissue 
RT-qPCR 16s 
rRNA 67.1% 97.8% 
Rak 2013 
PJI 16 
Aseptic 51 Tissue 
Broad 16s 
rRNA RT qPCR 75% 94.1% 
Bemer 2014 
PJI 264 
Aseptic 35 Tissue 
RT qPCR 16s 
rRNA 73.3% 95.5% 
Rak 2015 
PJI 24 






























Aseptic 44 Tissue 
RT qPCR 16s 
rRNA 76% 95% 
Kuo 2018 
PJI 25 
Aseptic 189 Synovial fluid 
RT qPCR 
16s/28s rRNA 100% 99.5% 
Fink 2018 
PJI 27 
Aseptic 89 Synovial fluid 
RT qPCR 
16sRNA 55.6% 82%  
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1.1.1 Biomarker literature search 
The use of culture methods in diagnosing infection has long been established, 
however, the ear of ‘biomarkers’ is evolving in many disease entities including 
infection and cancer.  To identify current and proposed biomarkers for PJI, a 
literature search was carried out.  Databases Pubmed and Web of Science were 
searched using terms “Prosthetic joint infection” AND/OR “alpha defensin”, 
“leucocyte esterase” as these are biomarkers currently known and detailed in 
the diagnostic criteria and “biomarker”.  Inclusion Criteria: All clinical trials, all 
prospective and retrospective data reviews, human studies, prosthetic joint.  
Exclusion criteria: studies not in humans, review or meta-analysis articles, 
native joints.  It was deemed appropriate to include retrospective clinical data 
reviews in this report as high quality RCT’s are often challenging to initiate in 
orthopaedics, and this would allow for studies with large data series.  Searches 
retrieved a total of 96 articles which were screened by title and abstract for 
their relevance, with duplicate articles removed.  The following review focuses 
on discussing the papers and biomarkers which are include in the updated PJI 
MSIS 2018 and EBJS 2020 guidelines, other biomarkers and references are noted 




1.11.3 C-reactive protein 
C-reactive protein (CRP) is an acute phase protein synthesised in hepatocytes in 
response to any tissue damage including inflammation and infection.  In the 
healthy adult population normal CRP levels are <10mg/L and they rapidly 
increases after stimulus, reaching a peak at 48hrs.  CRP has a short half-life and 
is a readily available widely utilised blood test (Pepys, 1981).  In the setting of 
PJI diagnosis, both serum and synovial CRP tests are utilized.  In a study 
evaluating pre-operative serum CRP in diagnosing PJI, a value >5mg/L was found 
to correlate with a subsequent diagnosis of PJI (Windisch et al., 2017).  A 
number of publications have questioned the reliability of serum CRP as a 
biomarker for PJI diagnosis.  In one retrospective study, which looked at 73 
patients with culture positive PJI, CRP was normal in 23/73 cases, missing nearly 
32% of PJI’s (Pérez-Prieto et al., 2017).  A second similar retrospective study 
found CRP to be normal (cut off value <10mg/L) in 77 of 215 (35.8%) of patients 
who again had a culture positive PJI (Akgün et al., 2018).  In both of these 
studies, it was noted a number of the cultures grew low virulence organisms 
including C.acnes, coagulase negative S.aureus and Corynebacterum.  
Furthermore, CRP monitoring post operatively following PJI treatment in the 
form of debridement, antibiotics, and implant retention surgery (DAIR) or two 
stage revision surgery found that values did not correlate well with infection 
relapse (Bejon et al., 2011).  These studies were assessing CRP as a lone marker 
for PJI, in normal clinical practice and the updated guidelines it is evaluated in 
the context of the whole clinical picture and diagnostic algorithm.  Measuring 
synovial CRP is a more recent development.  A study evaluating its use 
prospectively in revision hip and knee surgery, using the 2013 ICM definition of 
PJI to classify patients as aseptic or infected, found synovial CRP to be 
significantly higher in those with PJI vs aseptic revision 31.7mg/dL vs 1.02mg/dL 
P<0.001(Sousa et al., 2017).  This study proposed a synovial CRP cut off value of 
6.7mg/dL giving sensitivity and specificity values of 78.3% and 93.8% 
respectively.  Its diagnostic accuracy increased when it was used in combination 
with current synovial investigations - synovial WCC, resulting in 100% specificity 
(Sousa et al., 2017).  A further study evaluating synovial fluid from 89 patients; 
21 classified as PJI and 59 as aseptic as per microbiology results, 9 were 
excluded due to the inability to analyse the viscous fluid.  Sensitivity and 
specificity of synovial CRP were reported as 95.5% and 93.3% respectively (M. 
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Omar et al., 2015).  In the 2018 PJI diagnostic algorithm, markers were 
evaluated in a stepwise fashion in 1504 cases (684 PJI), beginning with the least 
invasive serum markers and using random forest analysis to calculate how 
important each variable was in predicting infection.  Of the three serum 
markers, CRP (>1mg/dL) carried the highest weight and was the most predictive 
of PJI (Javad Parvizi et al., 2018), however, synovial CRP was found to carry the 
lowest weight in random forest analysis for predicting PJI compared with other 
synovial investigations including WCC, % PMN, Leucocytes esterase and alpha 
defensin  Serum CRP is included in the 2020 EBJIS guidelines as the only blood 
‘biomarker’, but the authors caution against its use as a sole marker for PJI, 
synovial CRP is not included as a diagnostic marker (McNally et al., 2020).  To 
this author’s knowledge, synovial CRP is not routinely available in all clinical 
settings.   
1.11.4 Alpha Defensin 
Alpha defensins (AD) are a family of 6 antimicrobial peptides.  AD 1-4 are found 
in neutrophils, they are released in response to pathogen invasion and are able 
to disrupt the bacterial cell wall, therefore having bactericidal activity (Wang, 
2014).  AD has been an extensively studied biomarker in PJI and is credit to the 
field of translational medicine, from bench to clinically available bed-side test.  
The sensitivity and specificity of AD in diagnosing PJI is summarised in Table 1-7.  
Initially, AD was tested using a laboratory based ELISA method.  These studies 
reported the highest sensitivity (50%-100%) and specificity (95%-100%) values for 
AD.  Two studies reported lower values for sensitivity (50%, 78.6%) than the 
remaining five (94%-100%) studies and seem as outliers in their results, both of 
these studies included cases of chronic PJI and cultured low virulence organisms 
in a number of patients (Kleiss et al., 2019; Sigmund et al., 2018).  A number of 
these studies using the ELISA method included patients who had been treated 
with antibiotics showing that this biomarker has the potential to work in routine 
clinical practice (Bingham et al., 2014; Deirmengian et al., 2014a, 2014b, 2015).  
With the clinical limitations of a laboratory-based assay in providing a rapid 
diagnosis for PJI, it has since been developed into a bedside lateral flow test.  
Evaluation of this point of care test, Synovasure®, show sensitivity and 
specificity values from 20%-97% and 90%-100% respectively Table 1-7.   Studies 
that reported lower sensitivity values suggested possible interference with the 
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assay from blood or metal ions in the synovial fluid aliquot (Kasparek et al., 
2016), the presence of a draining sinus, which would lead to a lower 
concentration of defensins in the fluid (Gehrke et al., 2018) or a diagnosis of 
chronic infection.  In the random forest analysis for the 2018 MSIS update, AD 
performed as the second-best synovial marker for PJI.
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Table 1-7 Studies evaluating Alpha defensin in PJI 
Details of the 15 studies that assessed the utility of Alpha Defensin as a biomarker for PJI.  There 
were 5 studies that looked at the ELISA based laboratory method, 8 that used the lateral flow test 





Cut off value Method Sensitivity Specificity 
Bingham  2014 61 7.72mg/L ELISA 100% 95% 
Deirmengian C 
2014 (a) 
149 5.2mg/L ELISA 97% 96% 
Deirmengian C 
2014 (b) 
95 4.8mg/L ELISA 100% 100% 
Deirmengian C 
2015 
46 5.3mg/L ELISA 100% 100% 
Kleiss 2019 202 5.2mg/L ELISA 78.2% 96.6% 
























Sigmund I 2016 19 N/A Lateral flow 43% 94% 
Kasparek 2016 40 N/A Lateral flow 67% 93% 
Berger P 2017 121 N/A Lateral flow 97% 97% 
Balato G 2017 51 N/A Lateral flow 88% 97% 
Suda 2017 30 N/A Lateral flow 77% 97% 
Scholton R 2018 37 N/A Lateral flow 20% Not reported 
de Saint Vincent 
B 2018 
42 N/A Lateral flow 88.9% 90.6% 
Renz N 2018 212 N/A Lateral flow 54%-85% 96%-99% 
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1.11.5 Leucocyte Esterase 
Leucocyte esterase (LE) is an enzyme release by activated neutrophils at the site 
of infection and is in regular clinical use in the diagnosis of urinary tract 
infections.  The urine sample is applied to a test strip, a reagent on the strip 
lyses any neutrophils present in the sample, LE is released leading to a colour 
change.  A positive (++) result is indicated by dark purple. In recent years its use 
in detecting PJI has been investigated by a number of studies.  Initially, synovial 
fluid aspirates taken pre-operatively in cases of PJI in TKR were compared with 
TKR revision control cases.  Using only ++ as a positive result, they recorded a 
sensitivity of 80.6% and specificity of 100% for LE (J Parvizi et al., 2011).   
Following on from this, subsequent studies have compared LE in synovial fluid in 
cases of aseptic revision and PJI as per guidelines which were the gold standard 
at the time of their publication. Using ++ to indicate a positive result, reported 
sensitivities range from 66%-100% and specificities from 97%-100% (Wetters et 
al., 2012; Tischler, Cavanaugh and Parvizi, 2014; Colvin et al., 2015; 
Deirmengian et al., 2015).  Given the clear advantages of a result in 2 minutes at 
the bedside and readily affordable test kit, this would indicate LE should be 
added to the armoury of tests to investigate for PJI.  As with other synovial 
markers, interference with results has been noted from blood or metal ions 
(Shafafy et al., 2015; Wetters et al., 2012).  Identifying the level of colour 
change by eye may also introduce bias to this result.  To overcome this a more 
recent study used colourimetric analysis of the test strip rather than naked eye 
evaluation.  At a setting of 125 WBC on the test strip reader, the sensitivity and 
specificity were 81.8% and 92.9% respectively and the results correlated with 
known synovial WCC cut off values >1600ul/L (Shafafy et al., 2015).  In the 
updated 2018 diagnostic algorithm, LE is combined with synovial WCC.     
1.11.6 D-Dimer 
D-dimer is a fibrin degradation product, a marker of turnover of the coagulation 
system.  It has previously been used as a marker of venous thromboembolism 
and more recently as a marker of sepsis with its relation to disseminated 
intravascular coagulation seen in severe cases.  The rationale for testing D-dimer 
in the setting of PJI comes from two theories: Severely inflamed synovium in 
rheumatoid patients secretes high levels of fibrin, therefore, severely inflamed 
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peri-articular tissue in infection may also secrete high levels of fibrin, which is 
subsequently degraded to release d-dimer (Shahi et al., 2017).  Secondly, animal 
models of septic arthritis have shown significantly raised synovial D-Dimer 
(Ribera et al., 2011).  There has been one prospective study that has assessed D-
Dimer as a potential marker of PJI.  Blood samples were collected from 5 
different groups of patients: Primary arthroplasty, revision for PJI, revision for 
asepsis as per MSIS guidelines, 2nd stage re-implantation and patients with 
infection at any other site not including a joint.   The results showed that D-
Dimer was significantly higher in revision for PJI group (median value 
1110ng/mL) vs revision for asepsis (median value 299ng/ml) p<0.001 and it was 
more sensitive and specific than pre-operative CRP or ESR (Shahi et al., 2017).  
D-Dimer is included 2018 update to the PJI diagnostic algorithm grouped with 
CRP as a pre-operative blood test Table 1-5 (Javad Parvizi et al., 2018).  
1.12 Biomarker 
Biological markers or ‘biomarkers’ are used to aid diagnosis, drug response and 
prognosis in many diseases, including infection and cancer.  A number of 
biomarkers for PJI have been studied, some are discussed above (see section 
1.11.3, 1.11.4, 1.11.5) as they are included in current PJI diagnostic algorithms.  
With an increased understanding of PJI biofilm biology, potential new 
biomarkers are being studied, including:  
• Calprotectin – A protein in found in the cytoplasm of neutrophils and 
released upon neutrophil activation.  Currently used in the diagnosis of 
inflammatory bowel disease (Wouthuyzen-Bakker et al., 2018).   
• Procalcitonin – A peptide released into the bloodstream following 
bacterial infection (Bottner et al., 2007; Randau et al., 2014; Saeed et 
al., 2013; Sousa et al., 2017) 
• Adenosine deaminase – A protein involved in the purine metabolism 
pathway.  Its measurement can indicate immune cell activation in 
response to infection (Sousa et al., 2017).  
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• Presepsin - The soluble subtype of CD14, present of the surface of 
monocytes.  It is involved in pathogen recognition and shed into the 
bloodstream during activation of MMP-9, with downstream activation of 
the inflammatory response via IL6, TNFa and IL1b (Marazzi et al., 2018).  
• Interleukin -6 - A cytokine released by macrophages in response to 
infection and involved upstream in CRP production (Deirmengian et al., 
2014a; Ettinger et al., 2015; Majors & Jagadale, 2019; Sakamoto et al., 
1994; Wimmer et al., 2016), see Appendix A Table 6-1. 
However, the studies evaluating these markers report limitations, including 
challenges in establishing a reference range to define a positive result and 
evaluating the results in the context of known inflammatory diseases such as 
rheumatoid arthritis (Ettinger et al., 2015; Majors & Jagadale, 2019; 
Wouthuyzen-Bakker et al., 2018).  An ideal biomarker will be specific to PJI, 
therefore likely to be released from tissues in the joint, e.g. bone or synovium, 
in response to infection. It would be advantageous if the biomarker test was 
non-invasive, easily accessible from tissue such as blood to allow the test to be 
used if synovial fluid is not available. For the test to be robust and usable in 
clinical practice, it will require high levels of sensitivity and specificity and be 
cost effective.  The current cost of revision orthopaedic surgery to treat PJI can 
be up to 3-times more than for non-infective causes (£30011 vs £9655) (Kallala 
et al., 2015) and is associated with a high 5-year all-cause mortality rate, up to 
21.65% (Lum et al., 2018).  Therefore, identifying a novel biomarker or indeed a 
panel of novel markers to improve the diagnosis and subsequent treatment of 
this condition should be balanced against these known costs but would be 
attractive to reduce the significant burden of disease associated with PJI.   
1.13 Prosthetic joint infection work aims 
The literature now provides a detailed understanding of implant related 
infection from initiation of bacterial attachment, maturation and subsequently 
chronicity of biofilm infection.  This also includes how the immune response 
both reacts to and is excluded from this unique bacterial environment.  
Targeting the immune response to a pathogen as the diagnostic test is gaining in 
popularity, particularly as we enter the phase of personalised medicine.  The 
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first step in this process is to identify a consistent immune gene transcriptional 
signature in PJI cases.  To do this, this work will utilise next generation 
sequencing techniques and investigate the immune signature in biological tissue 
both local to (peri-articular tissue) and distant from (peripheral blood) the 
implant infection site.  Once an immune gene signature has been identified, 
larger cohorts can be used to validate it and investigate personalised prognostic 




 Chapter 2: Materials and Methods
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This chapter outlines the general materials, methods and equipment used for 
the duration of the current research.  Methods that were adapted at specific 
stages of the research are described in the appropriate later chapters. 
 Patient data collection 
Retrospective patient data was collected to assess the outcomes of the 
vancomycin wrap during ACLR surgery. Patient data collection was in accordance 
with procedures and protocols approved by the NHS West of Scotland Ethics 
Committee (REC14/WS/1035) and informed consent was obtained from all 
patients according to local procedures.  Data Search Criteria: Electronic 
operation note system (Bluespier®) was used to identify all anterior cruciate 
ligament reconstructions (ACLR) carried out between 1st July 2018 and 30th 
June 2019, in a single hospital trust, working across two clinical sites; Queen 
Elizabeth University Hospital and The New Victoria Hospital, Glasgow.  All ACLR 
both primary and revision were included between the search dates above.  
Those operations incorrectly coded as ACLR were excluded. The operation notes 





o Type of graft used 
o Primary or revision  
• Prophylactic IV antibiotics 
• Use of vancomycin wrap 
• 6 month follow up for infection 
o Bacterial species cultured 
o Treatment of infection: Antibiotic duration, further surgery 
 
Metadata was also collected retrospectively from those patients whom blood and 
synovial tissue were taken during orthopaedic revision arthroplasty surgery.  
Data was collected from electronic case notes and included age, sex, co-
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morbidities, clinical biochemistry and microbiology results pertaining to the time 
of surgery.  Patient data collection was in accordance with procedures and 
protocols approved by the NHS West of Scotland Ethics Committee 
(REC14/WS/1035) and informed consent was obtained from all patients 
according to local procedures    
 
 Ethics and Human tissue collection  
Human tendon tissue was obtained during surgery for anterior cruciate ligament 
hamstring reconstruction.  Patients were screened and the tissue discarded if 
there was a prior history of surgery to that joint – excluding previous ACL 
reconstruction, infection or malignancy.  Human synovial tissue and peripheral 
blood were obtained from patients undergoing Orthopaedic revision arthroplasty 
surgery.  Patients were excluded if there was a history of malignancy.  All tissue 
was collected in sterile containers containing RPMI.  Tissue was stored at 4oC in 
hospital until collection and delivery to the University Laboratory.  All samples 
were obtained from the New Victoria Hospital and Queen Elizabeth University 
Hospital Glasgow and used on the day of collection.  All patients gave prior 
written and informed consent in line with NHS Greater Glasgow and Clyde 
consent procedures and Glasgow University Ethics.  Surplus tissues samples, 
including synovial tissue and hamstring tissue, were collected as part of the 
NHSGG&C Bio-repository and Pathology Tissue Resource II [16/WS/0207], 
approval letter in Appendix C.  Blood samples were collected as additional tissue 
in line with NHSGG&C Additional Sample Tissue Resource to Support I3I Research 
[14/WS/1035] & [19/WS/0111], approval letter Appendix D.  All samples were 
taken by qualified medical practitioners. 
 Human tissue culture 
2.3.1 Tendon tissue 
Human tendon tissue was collected following surgery for ACLR and transported 
in sterile RPMI from the hospital site to the research laboratory.  For in vitro cell 
culture experiments, tenocytes were isolated and grown from the tendon tissue. 
The tendon tissue was cut into <0.5cm pieces using a scalpel and transferred to 
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a 25cm2 culture flask with 5ml of RPMI supplemented with 10% (v/v) faetal calf 
serum, 100U/mL penicillin, 100µg/mL streptomycin (Gibco, Scotland, UK), at 
37oC humidified atmosphere of 5% CO2.  Cell culture was maintained for 28 days.  
Cells were passaged with trypsin at subconfluency and used at second or third 
passage for in vitro experiments.  For ex vivo explant experiments, tendon tissue 
was cut into 1cm sections using a scalpel Figure 2-1.  These sections were 
transferred to a 24 well flat bottom cell culture plate and treated with 
experimental conditions for 1 hour at 37oC humidified atmosphere of 5% CO2.  
Supernatants were aspirated and stored for future protein quantitation analysis 
and replaced with RPMI for 16 hours at 37oC humidified atmosphere of 5% CO2.  
Following the 16-hour incubation, supernatants were aspirated and stored for 
future protein quantitation analysis.  The tissue was transferred to RNALater 
(Invitrogen) or 4% buffered formalin (ThermoFischer Scientific) for qPCR and 
immunohistochemistry analysis, respectively.  Tissue in RNALater was stored at 
4oC for 24 hours to allow the storage agent to penetrate the tissue, this was then 
stored at -20oC or proceeded directly to RNA extraction section 2.7.1.  For 
tendon biomechanical analysis, tendon tissue was cut into 3cm sections using a 
scalpel Figure 2-2.  The tissue was transferred to a 6 well flat bottom cell 
culture plate and treated with experimental conditions for 1 hour at 37oC 
humidified atmosphere of 5% CO2.  Supernatants were aspirated and stored at -
20oC, tissue was stored at -20oC for future biomechanical analysis.  Due to 
restrictions in place during the COVID 19 outbreak, biomechanical analysis was 




Figure 2-1 Images of the tendon ex vivo model 
Tendon was cleared of surplus muscle and cut into 1cm sections then transferred to a 24-well 






Figure 2-2 Images of tendon for biomechanical analysis 
Tendon was cleared of surplus muscle and cut into 3cm sections and transferred to a 6-well tissue 
culture plate in 3mls of media with experimental conditions.
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2.3.2 Synovial Tissue 
Synovial tissue was collected from patients undergoing Orthopaedic revision 
arthroplasty surgery.  Tissue representing synovium, was taken using a clean 
scalpel, and transported to the laboratory in sterile RPMI.  The tissue was 
sectioned into approximately 2 x 1cm sections for storage in 4% buffered 
formalin or RNALater.  Tissue in RNALater was stored at 4oC for 24 hours to allow 
the storage agent to penetrate the tissue, this was then stored at -20oC or 
proceeded directly to RNA extraction section 2.7.1, tissue in formalin was fixed 
at room temperature for 24 hours before transferring to 70% ethanol for paraffin 
embedding and analysis section 2.4.1.  Laboratory synovial tissue samples were 
annotated as PJI (infected) or aseptic control based on routine hospital clinical 
assessment which referenced the MSIS guidelines see Table 1-5 & Table 1-4 and 
microbiology results.   
2.3.3 Peripheral Blood 
Peripheral blood was obtained from patients prior to undergoing Orthopaedic 
revision arthroplasty surgery.  Blood was taken in 2.5ml Paxgene® tubes (BD 
Biosciences) and inverted 10 times to ensure mixing with the RNA stabilising 
reagent, which prevents RNAse enzymes degrading RNA.  The blood was sorted 
at -80oC within 24 hours of collection.   
 Histology and immunohistochemistry 
2.4.1 Synovial tissue 
Synovial tissue fixed in 4% buffered formalin was processed as per section 2.3.2.  
The tissue was subsequently dehydrated in graded alcohol and embedded in 
paraffin blocks.  The block was cut into to ensure the 5µm sections were 
representative of the whole tissue.  Consecutive sections of tissue 5µm thick 
were cut (Leica Microsystems, Germany).  The middle cut was stained with 
haematoxylin and eosin, re-hydrated in graded alcohol, and mounted onto a 
glass microscope slide with DPX mountant and a cover slip.  The stained slides 
were imaged using a light microscope (Olympus, DP22).  Un-stained sections 
were used in analysis by HTG molecular Diagnostics for tissue transcriptomics 
see section 2.7.5.  All synovial tissue embedding and cutting plus assistance with 
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haematoxylin & eosin staining was provided by Ms Fiona McMonagle (Technician 
Institute of Infection, Immunity and Inflammation, University of Glasgow) 
2.4.2 Tendon tissue 
Treated and control tendon explant tissue section 2.3.1, fixed in 4% buffered 
formalin, dehydrated in graded alcohol and embedded in paraffin, were used for 
haematoxylin and eosin staining and Caspase 3 antigen staining (Cell Signalling 
Technology, UK).  Sections of tissue 5µm thick were cut (Leica Microsystems, 
Germany), paraffin removed by xylene and rehydrated in graded alcohol.  At this 
stage, the tissue was either stained with haematoxyxlin and eosin, re-hydrated 
in graded alcohol, and mounted onto glass microscope slides with DPX mountant 
and a cover slip or, proceeded to Immunohistochemistry staining for antigen 
expression as follows.  Endogenous peroxidase activity was quenched with 3% 
(vol/vol) H2O2, and nonspecific antibody binding was blocked with 2.5% horse 
serum in TBST buffer for 30 minutes. Antigen retrieval was performed in 0.01 M 
citrate buffer for 25 minutes in a microwave.  Tissues sections were incubated 
with primary antibody and Isotype control diluted 1:125 in 2.5% (w/v) horse 
serum/TBST overnight at 4°C. After two washes, slides were incubated with 
Vector ImmPRESS Reagent kit as per manufacturer’s instructions for 30 minutes. 
The slides were washed and incubated with Vector ImmPACT DAB chromagen 
solution (1 drop per 1ml diluent) for 30 seconds, followed by extensive washing 
in water. Finally, the sections were counterstained with haematoxylin, 
dehydrated in graded alcohol and mounted in DPX with a coverslip. 
 MTT Cell viability assay 
The MTT assay is a colorimetric assessment assay which correlates with cell 
viability.  The yellow tetrazolium salt MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) is taken up by metabolizing cells and changed into 
a blue formazan product by reductase enzymes in the cytosol and mitochondria.  
The blue formazan product accumulates within viable cells, once lysed, the 
product can be measured and quantified by spetophotometry(Mosmann, 1983).  
To make a 10nM solution of MTT, 414.3mg of MTT (Sigma-Aldrich, Dorset) was 
dissolved in 100ml of PBS.  This solution was then sterile filtered with a 0.2µm 
filter and stored in the dark at 4oC until use. 
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2.5.1 Tenocyte viability 
Tenocytes were cultured with experimental conditions in a 24 well plate, 
following which supernatants were aspirated, and the cells re-suspended in 
250µl of MTT, incubated for 3 hours at 37oC/5% humidified CO2.  The 
supernatants were removed and the cells washed with sterile RPMI and 
incubated with 200µl DMSO for 10 minutes to dissolve the formazan product. 
This was transferred into a 96 well plate (100µl per well in duplicate) and read 
on a MTX TC II microplate reader (Dynex Technologies) at 540nm.  
 Protein Quantitation  
Protein quantitation in tendon supernatants was determined using enzyme linked 
immunosorbent assays (ELISA’s) (IL-6, IL-8, MMP-3, CCL2, Cytochrome C, Pro-
Colagen1α) and luminesces assays (Caspase 3) according to manufacturer’s 
instructions, Table 2-1.   
2.6.1 ELISA 
All ElISA’s were performed in 96 well half area high binding microplates 
(Corning™ Fischer Scientific) with volumes scaled accordingly. If required, plates 
were coated with 50µl/well of capture antibody, diluted as per instructions in 
PBS, sealed and incubated overnight at 4oC.  Following incubation, plates were 
washed once with wash buffer then blocked for 1 hour at room temperature with 
150µl/well of assay buffer.  During incubation, standards and samples were 
prepared in assay diluent.  The standard curve was made as per the instructions 
on the Certificate of Analysis with serial 2-fold dilutions from the top standard.  
Following incubation with assay buffer, the wells were aspirated and 50µl of the 
standards and samples were pipetted into appropriate wells, followed by 25µl of 
detection antibody diluted as per manufacturer’s instructions.  Plates were 
sealed and incubated with continuous shaking at room temperature for 2 hours.  
Following this, each well was aspirated and washed 5 times with wash buffer and 
50µl of Avidin-HRP diluted as per instructions added to each well.  The plate was 
sealed and incubated as previously for 30 minutes.  The wells were aspirated and 
washed 5 times and 50µl of TMB solution (ThermoFischer) was added to each 
well and incubated in the dark as above for a maximum of 15 minutes.  Once the 
desired colour change of the standards had been achieved, 50µl of 2M H2SO4 was 
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added to each well to stop the reaction.  Absorbance was recorded within 30 
minutes of this final step on a MTX TC II microplate reader (Dynex Technologies), 
measured absorbance 450nm and reference absorbance 650nm.
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Table 2-1 Elisa and Luminesces kits used for protein quantitation 
Details of the source, buffers and assay ranges for the ELISA and Luminescence kits used.  BSA- 














20, 2M H2SO4 in 
PBS 
IL-6 15.6 – 1000 





PBS Provided in kit 
0.05% Tween-









0.5% BSA & 
0.1% Tween-
20 in PBS 
0.05% Tween-




















Not required Not required  
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2.6.2 Luminescence assay 
Before beginning the assay, the Caspase-GLO 3/7 Buffer and lyophilized Caspase-
Glo 3/7 substrate were reconstituted to form Caspase-GLO 3/7 reagent at room 
temperature, by transferring the buffer into the substrate and mixing by 
inversion.  Using a white-wall 96 well plate (Corning™, Fischer Scientific) to 
reduce background luminesces, equal volumes (50µl) of reagent and supernatant 
were added to each well, along with experimental controls.  The plate was 
sealed and incubated for 1 hour at room temperature.  The luminescence was 
then recorded on a MicroBeta® TriLiux 1450 (Perkin Elmer life Sciences).  
 Quantitative polymerase chain reaction and gene 
expression analysis 
Treated and control tendon and synovial tissue, stored in RNALater section 2.3.1 
and 2.3.2 were used for gene expression analysis.  If required, samples were 
thawed on ice prior to RNA extraction 
2.7.1 RNA extraction from tissue 
RNA was isolated using PureLink™ mini kit (Life Technologies) as per 
manufacturer’s instructions.  The tissue was initially disrupted and homogenised 
in RLT buffer.  To prepare the samples, a scalpel was used to cut the tissue into 
<0.5cm pieces followed by metal bead homongenisation with 3 x 1 minute 
cycle’s at 35Hz (Qiagen TissueLyer LT).  Between each cycle the tubes were 
rested on ice for 1 minute.  The supernatant was removed and incubated in a 
new eppendorf with protease K (10µl protease K in 690µl of nuclease free H2O 
per tube) at 55oC for 15 minutes.  Following this, the sample was centrifuged at 
12,000rpm for 3 minutes.  The supernatant was removed, combined with an 
equal volume of 70% (v/v) ethanol in a new Eppendorf, mixed by pipetting and 
spun through an RNeasy spin column by centrifuging at 12,000g for 15 seconds.  
The flow-through was discarded and 700µl of wash buffer I was added and the 
column centrifuged as before.  A further wash step with 350µl of wash buffer II 
was performed and centrifuged as before, transferring the column to a new 
collection tube for DNase treatment.  10µl of DNase I mixed with 70µl RDD 
buffer (Qiagen) was added to each column and incubated at room temperature 
for 15 minutes.  Following this, a further wash step with 350µl of wash buffer II 
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was performed, the flow-through discarded and transferred to a new 2ml 
collection tube.  The sample was then centrifuged at 12,000g for 2 minutes with 
the lid open to dry the membrane.  The spin column was transferred to a 1.5ml 
collection tube and RNA eluted using nuclease free water.  RNA was quantified 
and purity checked using a Nanodrop 2000/200c (ThermoFischer), nuclease free 
water was used as a blank.  Absorbance of RNA was measured at 260nM, 280nM 
and 230nM.  The A260:280 ratio determines RNA purity, the A260:230 ratio 
determines the level of protein contamination.  RNA was either stored at -20oC 
until required or preceded straight to cDNA synthesis, section 2.7.2. 
2.7.2 cDNA synthesis 
cDNA was synthesized using High-Capacity cDNA synthesis kit (Applied 
Biosystems). 100ng of RNA was converted per reaction, unless there was 
insufficient RNA, in which case 80ng was used.  The reaction was assumed to go 
to completion and create 100ng of cDNA.  Briefly, RNA samples were diluted 
with nuclease free water to 10ng/µl and 10µl added to a 2 x high capacity cDNA 
master mix for a final volume of 20µl Table 2-2.  Tubes were placed in a thermal 
cycler (Applied Biosystems) for the reverse transcription reaction, Table 2-3.  
cDNA was diluted to 1ng/µl using nuclease free water and stored at -20oC.
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Table 2-2 High-capacity cDNA master mix  
Details of the reagents and buffers used per reaction to synthesise cDNA from RNA.  
Reagent Volume per reaction (µl) 
 
10x RT Buffer 2 
dNTP 0.8 
10x RT Random Primers 2 
Multiscribe™ Reverse Transcriptase 1 




Table 2-3 Programme settings for High-capacity cDNA synthesis 
 
Settings Step 1 Step 2 Step 3 Step 4 
Temperature 25oC 37oC 85oC 4oC 
Time (minutes) 10 120 5 ∞ 
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2.7.3 Gene expression analysis via quantitative PCR 
All primers were either obtained from the previously designed stocks in the 
laboratory or designed specifically for this project using Integrated DNA 
Technologies (IDT) and the PrimerQuest tool 
(https://eu.idtdna.com/Primerquest/Home/Index).  Details of the primers used 
in the project are detailed in Table 2-4.  Default settings for qPCR with 
intercalating dyes were used e.g. an optimum melting temperature of 62°C, GC 
content of 50%, primer size of 22 nucleotides and amplicon of 100nts. Where 
possible, primers were designed to overlap exon junctions, to increase 
specificity for mature cDNA.  Primers were tested for specificity using NCBI Blast 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). All qPCR primers were validated with 
a melt curve to ensure the presence of a single product without evidence of 
primer dimerization.  
Transcripts were analysed by qPCR in duplicate in a 96 well plate format. The 
10ul reaction was carried out using 5µl Powerup SYBR® Green (Thermo Fisher 
Scientific), 0.1µl of each forward and reverse primer (stock 100µM,Table 2-4) 
3.8µl of nuclease free water and 1µl of cDNA.  A non-template control, 
substituting 1µl of nuclease free water for cDNA was carried out for each primer 
to control for reagent contamination.  The plates were sealed and centrifuged 
for 30 seconds prior to running on Applied Biosystems StepOne Plus System.  
Cycling conditions were as follows: 10 minutes at 95°C, then 40 cycles of 95°C 
for 15 seconds to denature, and 60°C for 1 minute to anneal and extend.  
Samples were normalized to GAPDH or 18s housekeeping gene and where 
applicable fold change calculated using the following equations:  
Normalisation to housekeeping gene: 
2-ΔCT = 2-(CT gene of interest) – (CT housekeeping gene) 
Calculation of fold change: 
2-ΔΔCT = 2-ΔCT(variable) / 2-ΔCT(control)
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Table 2-4 qPCR Primers 
Forward and revere nucleotide sequences of the primers used in qPCR. 
Primer Forward (5’ – 3’) Reverse (5’ – 3’) 
GAPDH TCGACAGTCAGCCGCATCTTCTTT ACCAAATCCGTTGACTCCGACCTT 
18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
AIFM1 CAGTCAATGTTCTGGAGTGATTTG TTGTCTTGTGCAGTTGCTTT 
BCL2 AGGCTGGGATGCCTTTGT GACTTCACTTGTGGCCCAGATA 
BAX GGAGCTGCAGAGGATGATTG AGTTGAAGTTGCCGTCAGAA 
Caspase 3 TCATTATTCAGGCCTGCCGTG TGGATGAACCAGGAGCCATCC 
CCL2 CTC AGC CAG ATG CAA TCA ATG TGC TGC TGG TGA TTC TTC TAT 
Collagen 1a CAATGCTGCCCTTTCTGCTCCTTT CACTTGGGTGTTTGAGCATTGCCT 
Collagen 3a TAT CGA ACA CGC AAG GCT GTG AGA GGC CAA CGT CCA CAC CAA ATT CTT 
Decorin CGC CTC ATC TGA GGG AGC TT TAC TGG ACC GGG TTG CTG AA 
FADD GGA AGA AGA CCT GTG TGC AG GCA TCT TGG TGT CTG AGA CTT T 
FAS AGG GAT TGG AAT TGA GGA AGA CTA GCT TTC CTT TCA CCT GGA 
Fas Ligand ATA GGC AAG TCC AAC TCA AGG CAC AAG GCC ACC CTT CTT AT 
HMGB1 CTC AGA GAG GTG GAA GAC CAT CT GGG ATA TAG GTT TTC ATT TCT CTT TC 
Interleukin 6 CAC TCA CCT CTT CAG AAC GAAT GCT GCT TTC ACA CAT GTT ACT C 
Interleukin 8 GTG CAT AAA GAC ATA CTC CAA ACC GCT TTA CAA TAA TTT CTG TGT TGG C 
MMP 3 ACC CAC CTT ACA TAC AGG ATT G GTC ACC TCT TCC CAG ACT TTC 
Survivin GAA CTG GCC CTT CTT GGA G CTT GAA GCA GAA GAA ACA GCT G 
Tenascin C GTG CCA GGA GAC CGT ACC AC CTT TGG CTG GGT TGC TTG AC 
TNFr GAA GAA CCA GTA CCG GCA TTA T TGC ACA CGG TGT TCT GTT 
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2.7.4 Prosthetic joint infection patient blood transcriptomic 
analysis 
RNA was extracted from the blood using PAXgene® blood RNA kit following the 
handbook instructions for manual purification (handbook version 2 June 2015).  
The samples were removed from -80°C and stored overnight at 4°C to allow them 
to thaw.  They were then brought to room temperature for 2 hours before 
beginning extraction to allow full lysis of the cells.  Aliquots of 500µl were taken 
from each sample and transferred on dry ice to HTG Molecular diagnostics for 
analysis with their quantitative nuclease protection assay with a next generation 
sequencing platform.  This allows quantitative analysis of a pre-defined gene 
panel without nucleic acid extraction.  Briefly the method involves DNA nuclease 
protection probes flanked by universal wing sequences binding to the target RNA 
in the sample.  These nuclease protection probes can bind the target RNA in 
soluble and cross-linked biological matrix (eg: formalin fixed).  Universal DNA 
wingmen are then hybridised to the protection probe wing sequences.  S1 
nuclease is added which digests any non-hybridised RNA and any excess DNA 
wingmen.  This leaves only the target RNA bound to the nuclease protection 
probes and flanked by the DNA wingmen in a 1:1 ratio.  Heat denatures the DNA 
from the RNA probes, and allows for DNA amplification, quantification and 
sequencing Figure 2-3.  The laboratory work was carried out by Mr Ihab Botros, 
Mr James Cooley and members of the sample logistics and development teams 
(HTG Molecular diagnostics, Arizona).  Prior to release of data and analysis, all 
samples underwent three steps of quality control (QC).  QC0 involved spiking the 
samples with a positive control, less than 25% of readouts should come from this 
spiked sample.  Over this value and the sample was deemed to have too little 
RNA to proceed.  QC1 analyses read depth and QC2 looks for variance, which 





Figure 2-3 Schematic representation of HTG Molecular nuclease protection assay chemistry 
DNA nuclease protection probes, flanked by wingmen are hybridised to the target RNA in the 
biological sample.  Universal DNA wingmen are then added and bind to the wingmen on the DNA 
nuclease protection probes.  S1 nuclease is added which digests unbound RNA, excess DNA 
wingmen and DNA nuclease protection probe wings.  Heat denatures the bond between RNA and 
DNA nuclease protection probe and releases the DNA nuclease protection probe.  Library 
preparation involves adding tags – barcodes and sequencing adaptors to the DNA nuclease 
protection probes.  The labelled DNA nuclease protection probes are concentrated and pooled 
ready for sequencing.  DNAnpp = DNA nuclease protection probe.  Image created in BioRender, 
adapted form HTG Molecular sample analysis report VLP00498.   
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RNA extraction from the remainder of the PAXgene® blood was performed in the 
laboratory and proceeded as follows.  The samples were centrifuged at 3,000g 
for 10 minutes to pellet the RNA and the supernatant was discarded.  The size of 
the pellet was noted to give an explanation should the sample have a low RNA 
yield. RNase-free water (4mL) was added and the pellet resuspended before 
another spin at 3,000g for 10 minutes. Buffer BR1 (350µL) was added and 
vortexed to dissolve the pellet before transferring into a fresh 1.5mL 
microcentrifuge tube. Buffer BR2 (300µL) and proteinase K (40µL) were added, 
the mixture was vortexed for 5 seconds and then incubated in a shaking 
incubator at 55°C for 10 minutes to remove proteins from the sample.  The 
lysate was transferred to a PAXgene® shredder spin column and centrifuged for 
3 minutes at 20,000g to homogenise the sample.  The flow-through was then 
transferred to a fresh 1.5mL microcentrifuge tube, without disturbing the pellet, 
and 350µL of 100% ethanol was mixed with the sample. Thereafter, the sample 
was then run through the PAXgene® RNA spin column by centrifugation at 8,000g 
for 1 minute. The RNA from the sample was now bound to the column and the 
flow-through could be discarded.  Buffer BR3 (350µL) was added to wash the 
column and spun at 8,000g for 1 minute.  DNase (Qiagen) was added to the 
column and incubated at room temperature for 15 minutes to remove DNA 
contamination from the sample. The column was washed with 350µL of buffer 
BR3 then again with 500µL of buffer BR4, both were spun at 8,000g for 1 minute. 
Another 500µL of buffer BR4 was added and spun at 8,000g for 3 minutes to 
ensure the column was dry.  The RNA was eluted from the column in 35µL buffer 
BR5, spun at 8,000g for 1 minute. An additional 35µL of buffer BR5 was eluted, 
to give a total of 70µL eluted product. The RNA sample was denatured by 
heating to 65°C for 5 minutes and chilled immediately on ice.  RAN yield was 
quantified using a QubitÔ RNA high sensitivity assay kit (Thermo Fisher 
Scientific) following the manufacturer’s protocol. Briefly, 1µL of sample was 
diluted in 199ul of working solution and the sample’s optical density 
was measured using the QubitÒ 3.0 Fluorometer and RNA quantity calculated. 
RNA samples were then stored at -80˚C until required.  
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2.7.5 Transcriptomics of synovial tissue FFPE samples  
The HTG molecular quantitative nuclease protection assay as described 
previously, is applicable to RNA in cross linked biological matrix eg: formalin 
fixed tissue samples, again using a lysis only step without RNA extraction, see 
section 2.7.4 and Figure 2-3.  This panel of genes was analysed in the formalin 
fixed paraffin embedded 5µm sections of synovial tissue to identify an immune 
signal unique to prosthetic joint infection.  The laboratory work was carried out 
by Mr Ihab Botros, Mr James Cooley and members of the sample logistics and 
development teams (HTG Molecular diagnostics, Arizona).  Prior to analysis, all 
tissue samples underwent three steps of quality control (QC) as previously 
described in section 2.7.4  Data was provided as raw read counts.
 Statistical analysis   
All Statistical analysis were performed using GraphPad Prism 6 Software.  On all 
applicable data, a test for normal distribution was carried out.  When data 
followed a normal distribution, parametric tests were used.  When data was not 
normally distributed or there was insufficient data to test for normality non-
parametric tests were used.  Specific statistical tests used and details of 
multiple comparisons are detailed in the relevant results section and figure 
legends.  Significance was set at p<0.05.  
 Bioinformatics 
Analysis of sequencing data were performed by John J Cole, Bioinformatician at 
University of Glasgow using in house software (Searchlight 2).  Statistical 
significance was set at p<0.05.   
 
 
 Chapter 3: A novel next generation sequencing 





The diagnosis of PJI remains a challenge, despite international consensus 
meetings to update diagnostic criteria, there remains no unified diagnosis or 
test.  Recent publications have adopted a step wise algorithm approach to 
diagnosis, however, the cut off values and tests included in each of these 
algorithms differs (McNally et al., 2020; Javad Parvizi et al., 2018).  
Microbiology culture identifying an infective organism remains a gold 
standard for diagnosis and rationalising antimicrobial treatment.  This leaves 
a challenging ‘culture negative’ cohort formed of three groups; a clinically 
infected implant but no bacteria can be grown, usually due to prior 
antibiotics or biofilm bacteria not growing on traditional agar plates; a low 
grade PJI were clinical markers and investigations are inconclusive but 
clinical suspicion is high and, true culture negatives.  Culture negative results 
can occur in around 7-15% of cases of suspected PJI (Berbari et al., 2007; 
Palan et al., 2019).  Multiple factors such as low virulence organisms or 
inadequate sampling are thought to be involved, however, prior 
administration of antibiotics is thought to be the principle reason (Berbari et 
al., 2007).  In clinical practice, culture negative samples are evaluated with 
molecular techniques in the form of broad PCR for bacterial 16s RNA.  Results 
from previous trials analysing this method have been summarised previously 
Table 1-6 they show 16s RNA PCR results do not consistently out-perform 
standard culture methods.  Possible reasons for this include sample 
contamination and detection coming from dead bacteria leading to a false 
positive result.  Furthermore, the literature has reported technical 
challenges when poly-microbial infections are present.  Other limitations 
include cost and availability of technology – usually only in centralised areas 
with samples having to be transported for analysis.  Currently researched 
methods to improve molecular diagnostics include Multiplex PCR, cartridge 
systems and NGS see Appendix B Table 6-2 and Table 6-3 for a summary of 
the current literature.   
Knowledge of the immune response to implant related infections and biofilm 
has led to a number of ‘biomarkers’ for PJI, including Leucocyte esterase and 
Alpha defensin, which are both included in the updated the 2018 PJI 
diagnostic algorithm (Javad Parvizi et al., 2018) and Interleukin–6 which has 
75 
 
been the subject of recent research see Appendix A Table 6-1 .  Immune 
markers have advantages over molecular sequencing techniques, they are not 
susceptible to DNA contamination and can be developed into ‘bedside’ tests, 
however, at the present time, they cannot guide antimicrobial treatment as 
they don’t provide bacterial genus level information.      
In this chapter, clinical samples from revision arthroplasty surgery are 
sequenced using a novel technique, involving a selected immune gene panel.  
This technology allows RNA sequencing to be performed on formalin fixed 
tissue, which historically, due to issues with protein cross-linking was not 
available.  Furthermore, the sequencing method has been developed to 
eliminate extraction steps; reduce analysis time and sample volume, whilst 
reducing possible sources of contamination and false positive results.  
Focusing on a specific immune gene panel aimed to eliminate spurious results 
seen with whole genome sequencing in PJI, whereby biologically unrelated 
genes can be significantly upregulated (Mohamed Omar et al., 2017).  In 
previous research, peri-prosthetic tissue samples have shown low sensitivity 
when evaluated with traditional culture (Walker et al., 2020) and 16s RNA 
PCR techniques (Marín et al., 2012; Ryu et al., 2014).  This was potentially 
due to small tissue sample size and spatial distribution of bacteria.  We 
therefore analysed this sequencing technology in blood, a more easily 
accessible biological tissue and one that would allow us to ascertain if local 
tissue changes are reflected systemically.  These results document the first 
time the immune gene response panel, developed by HTG molecular, has 
been evaluated in an orthopaedic cohort including PJI tissue, aseptic tissue 
and blood.      
 Aims & Hypothesis 
• Collect and analyse patient metadata for aseptic and PJI patient cohorts. 
• To use formalin fixed synovial tissue and blood collected in PAXGene® 
tubes, to evaluate an immune gene panel and identify a gene expression 
signature with PJI. 
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• To identify if an immune molecular signature from tissue and blood can 
stratify patient cohorts into aseptic control and PJI.  
• To identify if an immune molecular signature from tissue and blood can 
stratify the PJI by bacterial strain or chronicity of infection. 
To initiate infection, bacterial pathogens present unique combinations of 
pathogen-associated molecular patterns to specific pattern-recognition 
receptors expressed on immune cells.  Based on this I hypothesised that an 
immune signature in the tissue and blood would discriminate infectious (PJI) 
from aseptic (control) cohorts.  Furthermore, with the understanding of 
biofilm biology and the shielding of bacteria in mature biofilm, I hypothesised 
that chronicity of infection would affect this immune signature.  Blood 
represents a reservoir and a distribution vehicle for both bacteria and cells of 
the immune system, therefore, it was hypothesised, that a unique immune 
signature would also be found from infected PJI samples in blood.    
 Methods 
3.3.1 Patient Metadata 
Clinical patient data, along with microbiology results, were collected from 
electronic hospital records [Glasgow University Ethics codes 14/WS/1035, 
IMI_2018_06_A, IMI_2018_05_S].  This was used to annotate samples as 
infected or aseptic and to stratify into analysis cohorts including: acute and 
chronic infection, age, sex and anatomical location as shown in Table 3-1.  
The 2014 MSIS criteria were applied to define acute and chronic infection 
using clinically available data Table 3-2 (Javad Parvizi & Gehrke, 2014).  
Hospital microbiology protocol reports the white cell count of synovial fluid 
from the Gram film of a centrifuged deposit and reports this as the number of 
cells per high-powered field as +, ++ or +++.    
3.3.2 Tissue in formalin  
Surplus tissue was collected from patients undergoing revision arthroplasty 
surgery, fixed in formalin and cut into 5µm sections as detailed in methods 
section 2.4.1.  This tissue was analysed by HTG Molecular as described in the 
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methods section 2.7.5.  Gene expression raw data analysis was conducted by 
John J. Cole (Bioinformatics, Institute of Infection, Immunity and 
Inflammation, University of Glasgow) and visualised using in-house RNA 
sequencing software Searchlight (version 2.0) Figure 3-1.  
3.3.3 Peripheral blood in PaxGene® tubes  
Peripheral blood was collected into PAXGene® tubes from patients prior to 
undergoing revision arthroplasty surgery as detailed in methods section 2.3.3.  
Whole blood samples (500µL) were analysed by HTG Molecular as described in 
methods section 2.7.4.  Gene expression raw data analysis was conducted by 
John J. Cole (Bioinformatics, Institute of Infection, Immunity and 
Inflammation, University of Glasgow) and visualised using in house RNA 




Figure 3-1 Flow diagram representing clinical sample journey from patient to results 
Tissue and blood samples were collected from each patient in sterile RPMI media and 
PAXGene® tubes.  An aliquot of blood was taken and sent to HTG molecular for analysis.  
RNA was extracted from the remaining PAXGene® blood sample and stored at -80oC pending 
validation of the immune signature.  Tissue samples were fixed in formalin and then cut into 
5µm sections onto a glass microscope slide.  Slides were sent to HTG molecular for analysis.  
RNA was extracted from the remaining tissue and stored at -20oC pending validation of the 
immune gene signature.  Due to COVID-19 the immune signature was not able to be validated 





 Results  
3.4.1 Patient Metadata 
Surplus biological samples were collected from twenty-four patients for 
sequencing; clinical and microbiological details of this cohort are shown in 
Table 3-1.  There was no significant difference in age between the PJI and 
aseptic control cohort (66 vs 72, p=0.2), and no significant difference in 
male: female ratio.  The majority of samples were from hip or knee revision 
arthroplasty, with only two samples from shoulders, however, this reflects 
clinical practice, with shoulder arthroplasty being less common than hip or 
knee.  Stratification into acute and chronic infection cohorts was completed 
as per the 2014 MSIS guidelines (Javad Parvizi & Gehrke, 2014) using clinical 
history, biochemistry and microbiology results from electronic hospital 
records, Table 3-2.  Figure 3-2 shows the pre-operative CRP (A) and white 
cell count values (B) for all 24 patients.  The PJI cohort had significantly 
higher CRP and WCC compared with the aseptic cohort, however, these 
markers alone did not completely separate out the groups. Pre-operative 
values were chosen as inflammatory markers rise following surgery and it 
remains unclear how long post-surgery these acute phase reactants remain 
elevated.  In the aseptic cohort, following extended microbiology culture, 
two tissue samples reported a positive result.  In the first case (A027116), 1 
out of 4 tissue samples sent to microbiology grew bascillus simplex, in the 
second case (A027118) 1 out of 5 tissue samples sent to microbiology grew 
bascillus cirulans.  Both of these organisms are low virulence and were 
deemed by hospital microbiology multidisciplinary team review to be 
contaminants and were therefore not treated as PJI.  Associated 
inflammatory markers in both of these cases were low (CRP 5 & 5.3, WCC <1 
& 3.4) and therefore these samples remained assigned to the aseptic cohort.      
Designated aliquots of PAXgene® blood were used for sequencing, RNA was 
extracted from the remaining blood as described in methods section 2.7.4.  
The quantity of RNA extracted from each sample is detailed in Table 3-1.  
This RNA was stored at -80oC pending validation of a blood gene signature, 
however, due to COVID-19 restrictions this work could not be completed.
80 
 
Table 3-1 Patient Metadata of sequencing cohort 
Clinical and microbiological details of the patient cohort used by HTG Molecular for tissue and PAXGene blood sequencing.  Prosthetic joint infection N=12, aseptic control 
N=12.  No significant difference in average age, 66 years in infected cohort vs 72 years in aseptic p=0.2, analysis by t test. No significant difference in male: female ratio 
Fischer’s exact value 1.0.  One tissue sample failed QC (Quality control) and four blood samples produced insufficient library for sequencing.  Strep = Streptococcus, 














A027096 A028478 43 M Hip Strep mitis/oralis Acute Fail 4864 Pass Sufficient 
A027097 A028479 87 F Hip Staph capitis Chronic Pass 4864 Pass Sufficient 
A027098 A028480 74 M Knee Strep Group B Acute Pass 5312 Pass Insufficient 
A027099 A028481 86 F Hip Strep Group G Acute Pass 3744 Pass Sufficient 
A027100 A028482 54 M Knee Strep Group B Acute Pass 4704 Pass Sufficient 
A027101 A028483 47 M Hip Staph aureus Acute Pass 4016 Pass Sufficient 
A027102 A028484 74 M Hip Staph epidermidis Chronic Pass 4528 Pass Sufficient 
A027103 A028485 69 F Knee Pasturella Chronic Pass 2944 Pass Insufficient 
A027104 A028486 74 F Knee Strep Gallolyticus Acute Pass 3440 Pass Sufficient 
A027105 A028487 51 M Hip H. Influenza Chronic Pass 3424 Pass Sufficient 
A027106 A028488 70 F Knee Staph caprae, capitis 
Chronic Pass 2576 Pass Sufficient 
A027107 A028489 64 M Hip Strep mitis/oralis Acute Pass 4160 Pass Sufficient 
















A027109 A028491 62 M knee Aseptic N/A Pass 3776 Pass Sufficient 
A027110 A028492 79 F Knee Aseptic N/A Pass 2400 Pass Sufficient 
A027111 A028493 69 F Knee Aseptic N/A Pass 2944 Pass Sufficient 
A027112 A028501 79 M Hip Aseptic N/A Pass 5088 Pass Sufficient 
A027113 A028494 62 F Shoulder Aseptic N/A Pass 4384 Pass Sufficient 
A027114 A028495 67 M Knee Aseptic N/A Pass 3504 Pass Sufficient 
A027115 A028496 58 F Knee Aseptic N/A Pass 3280 Pass Insufficient 
A027116 A028497 76 F Shoulder Aseptic N/A Pass 4112 Pass Insufficient 
A027117 A028498 72 M Hip Aseptic N/A Pass 4080 Pass Sufficient 
A027118 A028499 60 F Knee Aseptic N/A Pass 3728 Pass Sufficient 
A027119 A028500 80 M Hip Aseptic N/A Pass 2496 Pass Sufficient 
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Table 3-2 Microbiology and biochemistry results for infected tissue cohort 
Clinical and laboratory details stratifying tissue samples into acute or chronic infection cohorts.  
Stratification as per 2014 MSIS guidelines (Javad Parvizi & Gehrke, 2014).  CRP= C-reactive 
protein, LE = Leucocyte esterase, HPW = high-powered field, WCC = white cell count per HPF 
+<5, ++5-9, +++>10, N/A = not available.    
Sample ID Duration 
of 
symptoms 










A027096_1 2 days 173 N/A Nil +++ 4/4 3/3 
A027097_1 4 months 15 N/A + + 3/5 1/2 
A027098_1 3 days 397 N/A Nil N/A 1/1 1/1 
A027099_1 2 days 253 N/A ++ ++ 1/5 1/2 
A027100_1 2 days 349 N/A ++ +++ 5/5 2/2 
A027101_1 9 days 372 N/A +++ N/A 6/6 0/0 
A027102_1 2 years 3 N/A ++ + 2/4 0/1 
A027103_1 11 months 70 N/A + + 4/4 1/2 
A027104_1 1 days 77 N/A + +++ 5/5 3/3 
A027105_1 7 months 81 N/A +++ ++ 2/5 1/2 
A027106_1 18 months 54 N/A ++ +++ 4/6 1/1 





Figure 3-2 Serum and plasma inflammatory markers for aseptic and PJI sequencing 
cohort 
(A) Serum CRP values, (B) Plasma WCC and (C) CRP plotted against WCC, aseptic shown in 
blue N=12, PJI shown in red N=12.  Analysis by unpaired t test, **p<0.01, ****p<0.0001.  WCC 
= white cell count (normal range  4.0-10.0 x109/L) (McBrearty & Moffat, 2021), CRP = C 













































































R2  = 0.5679
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3.4.2 Tissue & blood sequencing quality control and bias 
Sequencing results from the FFPE tissue and PAXgene blood samples 
underwent three levels of post sequencing quality control (QC) before data 
analysis.   
All FFPE tissue samples passed QC1, which has a minimum read depth cut-off 
to identify and exclude low expressers, and QC2 which defines a minimum 
threshold for biological variance, as normal clinical samples should have 
variance between expression of genes.  One tissue sample (A027096) failed 
QC0 quality check, Table 3-1; as the proportion of the sample (<75%) vs. 
spike (>25%) in positive control reads was too low, determining low sample 
quantity. The failed sample was re-submitted for re-evaluation, however 
failed QC again and was therefore excluded from future analysis.   
Four of the twenty-four blood samples (two infected and two aseptic cohort) 
had insufficient library concentration for sequencing, therefore, PAXgene 
blood sample results are for the remaining 20 patient samples.  All 20 
PAXgene samples passed post sequencing QC metrics, Table 3-1.     
The gene expression data was assessed for sources of bias that could affect 
the results using partition variance analysis.  For the tissue samples, ‘status’ 
that is subdivided into aseptic, acute infection or chronic infection, had the 
largest effect on the results followed by joint location which given the 
anatomical and surgical differences in hip, knee and shoulder arthroplasty 
was not unexpected.  Patient age and sex had minimal affects and therefore 
the data was not adjusted prior to analysis.  Variance partition analysis of the 
blood results showed that age and sex had the biggest effect on results.  This 
result was expected given previous research has demonstrated the effects of 
age and sex on gene expression results (Bongen et al., 2019), data was 
therefore not adjusted for these variables.  Bacterial strain had an increased 
effect on results than status, in contrast to the FFPE tissue results and 




Figure 3-3 Variance partition analysis 
Graphs showing the percentage of variance attributable to each factor: Age by decade, sex, 
bacterial strain, anatomical joint and status – acute infection, chronic infection or aseptic control 
for (A) FFPE joint tissue and (B) PAXgene® blood samples.  Tissue shows that status - 
acute/chronic infection or aseptic - has the biggest effect on the results.  PAXgene® blood 





3.4.3 FFPE Tissue sequencing: PJI vs aseptic  
The comparison of aseptic vs. PJI tissue gene expression, initially using 
Principle Component Analysis (PCA) showed that aseptic samples were 
clustering separately to infected tissue Figure 3-4A.  Aseptic samples in PC1 
vs PC2 cluster to the left of the graph and centrally in PC3 vs PC4. The PJI 
samples separated and dispersed form the centre on PC3 vs PC4 in contrast to 
the aseptic samples and showed a separate cluster to the left of midline on 
PC1 vs PC2, corresponding to a potential sub group within PJI Figure 3-4A.  
Differential expression analysis (threshold adj. p<0.05 and absolute log2fold-
change of >1) identified 65 genes differentially expressed between aseptic 
and PJI tissue. Of these 44, were significantly up-regulated and 21 
significantly down regulated in PJI Figure 3-4B.  Hierarchical clustering of 
these significantly differentially expressed genes showed the groupings which 
defined aseptic and PJI groups Figure 3-4C.  Although the heatmap 
demonstrated clear clustering of the two groups, this was not uniform across 
all samples within a group, particularly in the PJI group, where there was a 
number of high expressers, shown in red.  We hypothesised that this could 
relate to the findings from the PCA plots Figure 3-4A, that there were 
subdivisions of the PJI cohort.  It was important to establish that the 
significantly differentially expressed genes in the PJI cohort vs the aseptic 
cohort were biologically relevant.  Illustrated in Figure 3-5A, the significant 
genes belonged to gene sets involved in ‘Cell chemotaxis’ and ‘Response to a 
molecule of bacterial origin’. A breakdown of the significant genes involved 
in each of these pathways is shown in Figure 3-5B.  Further analysis of the 
significantly up-regulated genes was carried out using Area Under the 
Curve/Receiver Operating Characteristic curve (AUC/ROC), to establish the 
performance of the immune gene panel in distinguishing PJI versus aseptic.  
Figure 3-5C shows the AUC/POC values when all significantly differentially 
expressed genes between aseptic and PJI on the panel were included.  This 
shows at a specificity of 100%, sensitivity was 85%.  A machine learning 
algorithm was then used to identify a smaller panel of key genes which could 
allow clinical application, whilst optimising sensitivity and specificity.  Figure 
3-5D shows the results from this algorithm that identified a 4 gene panel: 
G0S2, CXCL5, NR1D2 and DBP, giving a specificity value of 100% and 






Figure 3-4 Comparison of the gene expression between aseptic control and infected 
FFPE tissue  
(A) Gene expression data Principle component analysis (PCA) scatterplots showing PC1 vs 
PC2 and PC3 vs PC4.  The percentage of variation explained by each component is given in 
the x and y-axis.  (B) Volcano plot showing a comparison of gene expression between aseptic 
control and infected tissue. Significantly differential genes (adj p<0.05, absolute log2 fold 
change>1) are shown in red, non-significant genes shown in black.  A positive fold change 
indicates up regulation in infected n=44, a negative fold change indicates down regulated in 
infected n=21. (C) Hierarchically clustered heatmap of significantly differentially expressed 
genes (adj, p<0.05, absolute log2fold >0.0) between infected and aseptic control tissue 
samples.  Aseptic samples indicated by the red bar, infected samples by the blue bar.  Colour 


















Figure 3-5 Enriched gene sets infected versus aseptic control FFPE tissue 
(A) Summary bar chart showing the 10 most enriched gene sets for the significantly up 
regulated genes (adj p<0.05, absolute log2 fold change>1) in infected versus aseptic control 
tissue.  The x axis shows the –log10 enrichment p value, gene set name on the y-axis.  
Significantly enriched gene sets are shown in red, with the number denoting how many genes 
in that set are significantly expressed.  (B) Summary box plots of the two significantly 
differentially expressed gene sets in infected tissue.  The x-axis denotes the gene, the y axis 
plots expression values scaled into per gene z-scores.  Gene set database GO BP.  (C) Area 
Under the Curve/Receiver Operator Characteristic curve (AUC/ROC) for all significantly 
differentially expressed genes in tissue between aseptic and PJI.  (D) AUC/ROC curve 


































3.4.4 Blood sequencing: PJI vs aseptic     
The blood sequencing results from the aseptic and PJI cohorts show a less 
clear distinction between groups.  Using PCA, PC1 vs PC2 shows no clear 
clustering of aseptic vs PJI, however in PC3 vs PC4 there was evidence of 
central clustering of aseptic samples Figure 3-6A.  Differential expression 
analysis (threshold adj. p<0.05 and absolute log2fold-change of >1) identified 
17 significant genes, 6 significantly up-regulated in the PJI cohort Figure 3-6B 
& Figure 3-6C.  Hierarchical clustering of these significantly differentially 
expressed genes does not show clear gene groupings, as seen with FFPE 
tissue, with the PJI cohort results driven by two high expressing samples 
Figure 3-6D.  Of the six significantly up-regulated genes in the PJI cohort, 












Figure 3-6 Comparison of the gene expression in blood from aseptic control and 
infected cases 
(A) Gene expression data Principle component analysis (PCA) scatterplots showing PC1 vs 
PC2 and PC3 vs PC4.  The percentage of variation explained by each component is given in 
the x and y-axis.  (B) Volcano plot showing a comparison of gene expression between aseptic 
control and infected blood samples. Significantly differential genes (adj p<0.05, absolute log2 
fold change>1) are shown in red, non-significant genes shown in black.  A positive fold change 
indicates up regulation in infected. (C) Bar chart showing the number of significantly 
differentially expressed genes (p.adj < 0.05, absolute log2 fold > 1) in blood between infected 
and aseptic.  (D) Heatmap of significantly differentially expressed genes (adj, p<0.05, absolute 
log2fold >0.0) between infected and aseptic control blood samples.  Aseptic samples indicated 
by the red bar, infected samples by the blue bar.  Colour intensity represents expression level; 








3.4.5 FFPE Tissue sequencing: Acute vs chronic PJI 
Previously described clustering of the PJI results on PCA raised the hypothesis 
that the immune signature from tissue could distinguish sub-groups of a PJI 
cohort.  Using the 2014 MSIS criteria (Javad Parvizi & Gehrke, 2014) the PJI 
cohort was divided into acute N=6 and chronic N=5 infection based on 
available clinical data Table 3-2.  Comparing acute with chronic PJI via PCA 
plots showed on PC1 vs PC2 analysis that these two groups were clustering 
separately Figure 3-7A.  Differential expression analysis (threshold adj. 
P<0.05 and absolute log2fold-change of >1) identified 45 significant genes, 28 
significantly up-regulated and 17 significantly down regulated in acute 
infection Figure 3-7B.  Hierarchical clustering of these significantly 
differentially expressed genes, showed how they can separate the two 
infection cohorts Figure 3-7C.  These results suggested an underlying 
difference in immune signature in tissue from acutely infected and 
chronically infected tissue.   
To further evaluate this finding the aseptic cohort was included, to look for 
patterns of gene expression between the 3 groups.  The PCA plots showed 
that chronic infection had a tendency to cluster with aseptic control; PC1 vs 
PC2 to the left side of the plot, PC3 vs PC4 centrally Figure 3-8A.  Differential 
expression analysis (threshold adj. p<0.05 and absolute log2fold-change of 
>1) evaluated the number of significant genes between the three groups; 
acute vs aseptic comparison 407 significant genes, acute vs chronic 45 
significant genes and chronic vs aseptic 7 significant genes Figure 3-8B.  
Evaluation of the overall pattern of expression from the tissue using gene 
signatures showed that signature 1 identified a pattern of expression similar 
between the aseptic and chronically infected tissue Figure 3-8C and that 
associated gene sets, which identify biological activity related to these 
genes, did not fit clinically with response to infection Figure 3-8D.  Signature 
2, a pattern expressed by acutely infected tissue, Figure 3-8E, showed 
significantly enriched gene sets that were consistent with response to 
infection, ‘Response to bacterium’, ‘Response to a molecule of bacterial 
origin’ and ‘Defence response to other organism’, Figure 3-8F.  These findings 
suggest that the overall gene expression of the PJI cohort was largely driven 
by the acutely infected tissue samples.  We can also infer that chronically 
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infected tissue had a gene signature that trended towards aseptic tissue and 


































Figure 3-7 Comparison of the gene expression in synovial tissue between acute and 
chronic infection 
(A) Gene expression data Principle component analysis (PCA) scatterplots showing PC1 vs 
PC2 and PC3 vs PC4.  The percentage of variation explained by each component is given in 
the x and y-axis.  (B) Volcano plot showing a comparison of gene expression between acute 
and chronically infected tissue.  Significantly differential genes (adj p<0.05, absolute log2 fold 
change>1) are shown in red, non-significant genes shown in black.  A positive fold change 
indicates up regulation in acute infection N=28, a negative fold change indicates down 
regulation in acute infection N=17. (C) Hierarchically clustered heatmap of significantly 
differentially expressed genes (adj, p<0.05, absolute log2fold >0.0) between acute and chronic 
infection.  Acute infection shown by the red bar, chronic infection blue bar, significant genes on 
the y axis.  Colour intensity represents expression level; blue represents low expression, red 















Figure 3-8 Comparison of gene expression in aseptic control, acute and chronically 
infected FFPE tissue 
(A) Gene expression data principal component analysis (PCA) scatterplots showing PC1 vs 
PC2 and PC3 vs PC4.  The percentage of variation explained by each component is given in 
the x and y-axis. (B) Volcano plots showing the comparison of gene expression in acute vs 
aseptic, acute vs chronic, chronic vs aseptic.  Significantly differential genes (adj p<0.05, 
absolute log2 fold change>1) are shown in red, non-significant genes shown in black.  A 
positive fold change indicates up regulation.  (C) Violin plot showing the pattern of expression 
for signature 1 across the 3 sample groups: aseptic and acute and chronic infection shown on 
the x-axis with mean gene expression value for the signature on the y-axis. (D)  Summary bar 
chart showing the 10 most enriched gene sets for Signature 1.  Significantly up regulated gene 
sets (adj P<0.05, absolute log2fold change <1) shown in red.  Signature 1 indicates biological 
similarity between aseptic and chronic infection. (E) Violin plot and (F) Summary bar chart 
showing the pattern of expression for Signature 2 which demonstrated biological difference in 
acute infection.
A
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3.4.6 Blood sequencing: Acute vs chronic PJI 
Analysis of the gene expression from aseptic vs PJI cohort had previously 
shown no clear separation in the groups Figure 3-6, identifying only 17 
significantly differentially expressed genes.  Further sub-analysis of this PJI 
cohort was therefore not carried out.   
3.4.7 FFPE tissue sequencing: Bacterial strain 
Tissue samples were annotated by bacterial strain as per hospital 
microbiology data.  From published literature, around 50% of PJI cases are 
caused by S.aureus including coagulase negative staphylococcus.  The 
remaining infections are caused by polymicrobial, Streptococcal or low 
virulence anaerobic bacteria, with a much broader range of pathogens than 
seen with native joint septic arthritis (Tande & Patel, 2014). In this study 
Staphylococcal (n=4) and Streptococcal (n=5) were the most common 
bacteria, there were other (n=2) bacteria present, Table 3-1.  Analysing gene 
expression, initially by PCA plots, showed no clear clustering of bacterial 
groups Figure 3-9A.  Focusing on staphylococcal and streptococcal bacteria 
again there was no distinct clustering in gene expression on PCA plot in tissue 
Figure 3-9B.  Differential expression analysis (threshold adj. p<0.05 and 
absolute log2fold-change of >1) identified 6 genes with significantly 
differential expression between staphylococcal and streptococcal cohorts 
Figure 3-9C. From these results, FFPE tissue immune gene expression did not 





Figure 3-9 Comparison of gene expression in infected FFPE tissue by bacterial strain 
(A) Gene expression PCA scatterplots showing PC1 vs PC2 and PC3 vs PC4 for all samples, 
annotated by bacteria.  The percentage of variation explained by each component is given in 
the x and y-axis.  PC3 vs PC4 shows aseptic samples cluster centrally.  (B) Gene expression 
PCA scatterplot showing PC1 vs PC2 for tissues samples positive for Staphylococcal n=4 and 
Streptococcal n=5.  (C) Volcano plot showing the comparison of gene expression in infected 
tissue samples Staphylococcal vs Streptococcal.  Genes are represented by dots.  Significantly 
differential genes (adj p<0.05, absolute log2 fold change >0.0) are shown by red dots, non- 
significant genes are shown in black, a positive fold change represents significantly increased 










3.4.8 Blood sequencing: Bacterial strain 
Blood samples were annotated by bacterial strain using the same method as 
FFPE tissue.  PCA analysis of staphylococcal vs streptococcal showed 
separation of these two groups on PC1 vs PC2, suggesting an underling 
difference in gene expression Figure 3-10A.  Differential expression analysis 
(threshold adj. p<0.05 and absolute log2fold-change of >1) identified 98 
significant genes, 55 of which were significantly up-regulated and 43 of which 
were significantly down regulated in Staphylococcal infection Figure 3-10B & 
Figure 3-10C.  Hierarchical clustering of these significantly differentially 
expressed genes showed delineation into two groups displayed on the 
heatmap Figure 3-10D.  The most significantly up-regulated genes seen with 
Staphylococcal infection CD8A and CD8B are involved in the T cell immune 
response, with Streptococcal infection, Toll like receptor 5 (TLR5) was the 
most significantly up-regulated gene, this is involved in recognising bacterial 








Figure 3-10 PAXgene blood staphylococcal vs streptococcal gene expression analysis  
(A) Gene expression PCA scatter plot showing PC1 vs PC2 and PC3 vs PC4.  The percentage 
of variation explained by each component is given in the x and y-axis.  PC3 vs PC4 shows 
central clustering of aseptic control samples.  (B) Volcano plot showing a comparison of gene 
expression between staphylococcal n=4 and streptococcal n=5 infected blood samples. 
Significantly differential genes (adj p<0.05, absolute log2 fold change>1) are shown in red, non-
significant genes shown in black.  A positive fold change indicates up regulation in 
staphylococcal.  (C) Bar chart showing the number of significantly differentially expressed 
genes (p.adj < 0.05, absolute log2 fold > 1), between staphylococcal and streptococcal. Up-
regulated genes are higher in staphylococcal.  (D) Heatmap of significantly differentially 
expressed genes (adj, p<0.05, absolute log2fold >0.0) between staphylococcal (blue bar) and 
streptococcal (red bar).  Colour intensity represents expression level; blue represents low 
expression, red high expression.  (E) Violin plots showing the most significantly up-regulated 











Research in the field of PJI has developed an understanding of biofilm biology 
and the immune reaction to implants, leading to the development of 
‘biomarkers’ for use in PJI diagnostics.  This work reports the first use of a novel 
molecular technology to sequence FFPE tissue and blood, harnessing this 
technology to further characterise the immune gene expression changes seen in 
PJI and aseptic revision arthroplasty to identify immune markers for infection. 
The sequencing method, as described in methods section 2.7.4 and 2.7.5, uses 
NGS techniques.  NGS techniques allow high through-put whole genome 
sequencing and are increasingly being used in PJI research, showing high levels 
of concordance with traditional culture methods and positive results in situations 
of culture negative PJI (Chen et al., 2019; Sanderson et al., 2017; Street et al., 
2017; Tarabichi et al., 2018; Thoendel et al., 2018).  It has also been used in 
other areas of medicine where pathogen identification is challenging yet crucial 
including culture negative meningitis and infective endocarditis (Cheng et al., 
2018; Wilson et al., 2014).  NGS research has noted the issue of host DNA 
contamination, despite steps in the method to eliminate this.  In this pilot study, 
NGS was instead used to target the host, and sequence genes involved in the 
immune response to infection.  
This pilot study consisted of a cohort of 24 patients, sequencing data was 
available for 23 of the 24 tissue samples (96%) and 20 of the 24 blood samples 
(83.4%).  Within the cohort, there were no significant differences between PJI 
and aseptic groups in male to female ratio or patient age.  Twenty-two of the 
samples came from hip or knee revision surgery, with two from shoulder revision 
arthroplasty.  This represents clinical practice, as hip and knee surgery is more 
frequent.  The CRP and WCC values were significantly higher in the PJI group vs 
the aseptic control group.  These are both markers of infection and are standard 
clinical investigations included in all diagnostic algorithms for PJI.  As this was a 
pilot study of a new technology it was important to have distinction in known 
markers for the PJI and aseptic cohorts.  All PJI tissue samples were culture 
positive, despite this, two samples had low CRP values (3, 15) and five samples 
had low/normal WCC’s that overlapped with values in the aseptic control group 
Figure 3-2.  Previous studies have shown that these markers alone cannot 
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diagnose PJI (Akgün et al., 2018; McNally et al., 2020; Pérez-Prieto et al., 2017).  
Staphylococcus aureus is the most common pathogen associated with PJI 
however, in this infection cohort it was represented by 1 out of the 12 PJI 
samples.  Furthermore, all samples in the infection cohort were positive for one 
genus of bacteria, previous literature has noted the increased incidence of 
polymicrobial infection in PJI.  These findings may limit the conclusions of this 
pilot cohort.  Two of the cases in the aseptic cohort had one positive sample on 
extended culture, deemed to be a contaminant and associated with normal CRP 
and WCC values.  Possible sources of contamination include time of biopsy with 
skin or soft tissues, on transfer to the hospital laboratory and during analysis.  
Standardised protocols for surgical sampling and laboratory analysis are in place 
to try and limit these events, including the cautious reporting of one positive 
sample and the need for clinical correlation (Drago et al., 2019).  In this 
scenario, both cases were treated clinically as aseptic and during 3 months 
follow up did not represent with infection.  Furthermore, pre-operative 
antibiotics, if they were given, would have initiated treatment of the bacterial 
infection, and may potentially have affected the results.  In this clinical scenario 
they are more likely to have been prescribed pre-hospital to patients with acute 
PJI infection, displaying classical symptoms of joint swelling, acute pain and 
erythema.  The sequencing cohort were evaluated and with the available 
electronic clinical data, no patient received antibiotics in the 6 weeks prior to 
surgery.    
Sequencing results from the FFPE tissue samples showed evidence of clustering 
into two separate groups, on PCA plot Figure 3-4S (PC3 vs PC4), aseptic samples 
clustered centrally, with PJI samples scattered out from midline.  This 
demonstrated an initial proof of concept showing that there are global 
differences in immune gene expression between aseptic and PJI tissue, despite 
an implant being involved in both conditions, and, that this sequencing 
technology was able to detect that difference.  There were 65/2002 genes 
significantly differentially expressed between the PJI and aseptic cohort, which 
belonged to clinically relevant pathways involved in cell chemotaxis and the 
immune response to a bacterium Figure 3-5.  This initially seemed a low number, 
however, as noted earlier, an immune response was expected in both cohorts 
due to implant material.  The specific genes involved in pathways up-regulated 
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in PJI are primarily involved in neutrophil chemotaxis and differentiation 
(CXCL1, CXCL5, CXCL6, CCL20, S100A12, CSF3R) along with bacterial cell 
membrane recognition (LBP).  A previously published study analysed tissue from 
PJI to evaluate an immune signature, using PCR techniques and machine-
learning.  A ‘test’ cohort of samples was used to generate a 3-gene target of 
DEFA1-LTF-IL1β that identified a PJI diagnosis with an Area Under the Curve 
value of 97.6%.  This gene combination was then validated in a new cohort of 10 
samples, with a 100% concordance rate with microbiology results in the 
validation group (Fillerova et al., 2017).  These findings are similar to our 
results, which identified acute neutrophil immune genes in the PJI cohort.  In 
this study, the initial test cohort was much larger with 76 patients, N=38 PJI 
based on tissue microbiology and histology; the 3-gene target demonstrated 86% 
concordance with standard microbiology culture results, lower than the smaller 
validation group.  The larger cohort is likely to have captured a broader time 
frame of infections – from acute to chronic, that may have different underlying 
immune signatures.  A further study used tissue from revision arthroplasty and 
PCR techniques to evaluate the utility of Toll like receptors (TLR’s) as immune 
biomarkers for PJI. TLR’s are transmembrane receptors expressed on a variety of 
human cell lines, they recognise pathogens, including bacteria and viruses, and 
activate the immune response.  This study looked specifically at TLR1 and TLR6 
as these recognise bacterial lipoproteins.  At optimal threshold of 0.0097, TLR 1 
had sensitivity, specificity and AUC values of 95.2%, 100% and 0.995 respectively 
(Cipriano et al., 2014).  This again links with genes found from the sequencing 
reported in this work, LBP - lipopolysaccharide-binding protein, binds to 
bacterial produced lipopolysaccharide and signals via TLR’s to activate the 
immune response.  TLRs can be up-regulated in periprosthetic tissue from both 
PJI and cases of aseptic loosening (Tamaki et al., 2009).  Evaluation of TLR1 
from a subsequent tissue PCR study concluded it was not a marker to classify PJI 
from aseptic with a specificity value of 66.6% (Fillerova et al., 2017).  Therefore, 
LBP may be a more specific marker to bacterial infection than TLR1. 
Interleukin- 6 was also identified in tissue sequencing pathway analysis, a 
biomarker that has been extensively studied in the literature looking at its 
potential for PJI diagnosis.  Published studies have evaluated IL-6 in both serum 
and synovial fluid.  The sensitivity and specificity values vary, in serum they 
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range from 12%-100 for sensitivity and 58%-97% for specificity.  For synovial fluid 
the results for sensitivity range from 48.6%-89% and for specificity from 85.5%- 
97.6%, see Appendix A Table 6-1.  Here we show that IL-6 gene expression 
changes are present and significantly elevated in PJI tissue (aseptic 796.6 ± 
174.8 vs PJI 5233 ± 2862, mean ± SEM, normalised read count, p=0.0045).  These 
results concur with the findings of elevated IL-6 in synovial fluid, which like 
tissue, is local to the implant and infection. Results from the blood sequencing 
show a trend towards higher IL-6 gene expression in PJI vs aseptic, however this 
is not significant.  This result does not concur with previously published 
literature reporting serum IL6 protein higher in PJI (Bottner et al., 2007; Cesare 
et al., 2005; Ettinger et al., 2015; Gallo et al., 2018; Majors & Jagadale, 2019; 
T. Worthington et al., 2010), see Appendix A Table 6-1for serum sensitivities and 
specificities.  One case in the aseptic cohort with a previously noted 1/5 tissue 
contaminant positive culture correlated with a high IL-6 gene expression level.  
A further case in PJI group received 2 days of antibiotics prior to positive 
microbiology samples, this case correlated with a low IL-6 gene expression level.  
Levels of IL-6 return to normal faster that other inflammatory markers, including 
CRP, therefore these two outliers may have introduced bias to this small cohort.  
Poor performance of serum IL-6 has previously been noted in low-grade 
infection, with sensitivity only 12% (Grosso et al., 2014).  In this current study 
cohort four of the PJI cases were annotated as chronic infection, although this 
did not affect the FFPE tissue results, it may have limited the results seen in the 
PAXgene blood samples.  The significantly raised IL-6 gene expression levels seen 
in tissue correlates with published synovial fluid results, including those 
evaluating a point of care lateral flow test (Wimmer et al., 2016), suggesting IL-
6 may be a viable local biomarker for PJI.  
To assess the diagnostic utility of the tissue sequencing, along with sensitivity 
and specificity of immune gene markers in PJI, Area Under the Curve Receiver 
Operating Characteristic (ROC) curves were calculated.  Incorporating all 
significantly differentially expressed genes from the 2002 gene panel, resulting 
in a specificity of 100% and sensitivity of 85% Figure 3-5C.  Using machine 
learning, a specific 4-gene panel was generated (GOS2, CXCL5, NR1D2, DBP).  
Using a smaller panel makes this a more practical and useable diagnostic test in 
clinical practice Figure 3-5D.  As seen in previous work, a combination of genes 
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is likely to be needed given the high sensitivity of molecular methods and 
multiple pathway involvement from some genes.  The genes used in the panel 
are involved in cell cycle regulation (G0S2), neutrophil activation chemokine 
(CXCL5), vitamin D metabolism (DBP) and (NR1D2) which has a role in 
transcriptional activation of IL-6.  Vitamin D has been shown to be involved in 
the up-regulation of antimicrobial peptides. 
Further analysis of tissue sequencing results from the PJI cohort, stratifying into 
acute and chronic infection groups using the 2014 MSIS criteria (Javad Parvizi & 
Gehrke, 2014) showed underlying gene expression differences between these 
groups Figure 3-7 & Figure 3-8.  Aseptic controls and chronic infection had an 
underlying similar gene signature, which did not correspond to that seen with 
acute infection.  Established biofilm, which starts at implantation and forms 
over 4 weeks, is present with chronic infection and can shield bacteria from the 
immune system, dampening immune response (Arciola et al., 2018).  This may 
explain our results, finding only 7/2002 genes significantly differentially 
expressed genes between aseptic control and chronic infection.  All of the PJI 
tissue samples included were microbiology positive as this was a pilot of the 
sequencing technology, however, in clinical practice culture negative results can 
be seen in up to 15% of PJI cases (Berbari et al., 2007; Palan et al., 2019), 
usually when there has been an indolent time course of clinical symptoms or 
prior antibiotics.  Immune mediated markers therefore may be unable to 
diagnose infection in the setting of chronic or low grade PJI, an issue previously 
noted in studies evaluating CRP, ESR and IL-6 (Grosso et al., 2014; Piper et al., 
2010).  Further analysis identified one gene that was unique to chronic infection, 
ITGB8.  This gene codes for a membrane protein avβ8 that is present on T cells 
and is critical for T cell immune regulation during on-going inflammation.  
Regulatory T cells express high amounts of avβa on their cell surface that allows 
them to activate TGFβ from its latent form.  Activated TGFβ can then supress 
effector T cells (J. J. Worthington et al., 2015).  Our results showed that tissue 
from chronic PJI had significantly lower ITGB8 expression, than both acute 
infection and aseptic controls.  This suggests that there may be limited on-going 
T cell activated inflammation in the tissue from chronic PJI compared with acute 
infection or aseptic controls.  The majority of previous work looking at chronic 
bacterial infection has focused on mucosal infection – lung and gut.  This has 
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shown that persistence of infection is a balance between the pathogens ability 
to modify the immune response, as discussed previously with S.aureus in PJI 
biofilm see section 1.8 and the immune regulatory mechanisms (Young et al., 
2002).  Previous work looking at PJI associated biofilm has suggested that 
chronicity of infection is driven by an immune suppressed environment, whereby 
immature myeloid derived suppressor cells (MDSC’s) supress T cell immune 
function (C. E. Heim et al., 2014; Cortney E. Heim et al., 2018; Cortney E. Heim, 
Vidlak, & Kielian, 2015; Cortney E. Heim, Vidlak, Scherr, et al., 2015).  This is an 
emerging area of research in implant biofilm immunology.         
Sequencing results from the PAXgene® blood samples did not allow clear 
distinction between aseptic control and PJI cohorts.  There were N=4 chronic 
infections in the PJI cohort, with tissue results showing an immune signature at 
the local level, correlating with aseptic control.  For a signature to be identified 
in the blood, activated immune cells would have to leave the joint and enter the 
circulation.  The number of chronic infections and the limited local response 
they stimulated may have limited any systemic immune repose in blood.  The PJI 
cohort did show high expression of 3 markers, ELANE, DEFA4 and DEFA_FAMILY, 
all associated with Alpha defensin which is currently included in the 2018 
diagnostic algorithm as a synovial fluid test.  These results suggest that AD 
markers can be found in the blood of PJI patients and further work may be 
warranted in evaluating AD in blood.  Gene sequencing results from blood did 
show separation into two groups when the samples were annotated by bacteria, 
either staphylococcal or streptococcal Figure 3-10, suggesting that there is an 
identifiable difference in immune response to these bacteria.  The cohort was 
too small to allow for other bacteria to be included.  Previously published 
literature has detailed how different gene transcriptional profiles can be 
identified in blood from healthy individuals compared to patients diagnosed with 
sepsis secondary to community acquired pneumonia (Severino et al., 2014).  The 
gene signature identified in the 10 patient sepsis cohort was also found to 
correlate with patient outcomes.  The group reported that reduced gene 
expression of immune mediated markers was seen in the group with worse 
clinical outcomes (Severino et al., 2014).   A further study evaluated blood from 
paediatric patients who presented to hospital with signs of infection, normal 
hospital microbiology samples were analysed to identify the pathogen to allow 
105 
 
treatment.  Blood from these patients, analysed using a microarray hybridisation 
technique, identified a 30 gene unique transcriptional signature that 
differentiated E.coli from S.aureus infection.  This signature was developed on a 
20 patient training set and then evaluated on 40 test samples, showing 85% 
concordance with microbiology culture results (Ramilo et al., 2007).  More 
recent work has come from the field of respiratory medicine, specifically 
separating bacterial from viral infection, to limit the overuse of antibiotics and 
attempt to curb antibiotic resistance.  Gene transcription profiles from blood, 
using an RT-PCR platform diagnosed bacterial infection with 88% concordance 
compared with traditional pathogen based microbiological culture (Lydon et al., 
2019).  Individual pathogens interact with specific pattern recognition receptors 
on immune cells, therefore producing an individual immune response, with a 
unique transcriptional signature.  Using this theory, these studies have switched 
the diagnostic strategy, from pathogen based testing to individual patient 
immune response.  The data presented here is the first time a blood gene 
signature stratifying staphylococcal from streptococcal infection in a PJI cohort 
has been identified.  Previously, genus level bacterial information has only been 
available following microbiology culture, and more recently from molecular 
methods usually employed in the culture negative setting.  This process can take 
48-72 hours to prove culture negative and several days for molecular 16s RNA 
PCR analysis. Further assessment of this finding in a larger cohort may allow 
earlier identification of the micro-organism from a blood test, in known PJI 
cases, allowing antibiotic rationalisation.
 
 Chapter 4: The molecular effects of vancomycin 
on the anterior cruciate ligament graft 
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Anterior cruciate ligament reconstruction (ACLR) using patella and hamstring 
grafts is a routine and successful surgical procedure, with low reported levels of 
infection (0.14%-1.8%)(Burks et al., 2003b; Indelli et al., 2002; Torres-Claramunt 
et al., 2013).  As with all orthopaedic surgery involving implants or grafts, it is 
routine to administer prophylactic antibiotics prior to the procedure in order to 
reduce the risk of infection and septic arthritis, potentially serious 
complications(Carney et al., 2018).  Although, the ideal timing of administration 
has been debated, it is common practice to administer them prior to skin 
incision and tourniquet inflation(Bratzler & Houck, 2005; Bryson et al., 2016).  
The most common pathogen cultured in synovial fluid following ACLR infection is 
coagulase negative Staphylococcus species.  It is understood to be a contaminant 
of the graft, from either patient skin or graft preparation, coupled with the 
foreign body suture material inside the knee joint(Mouzopoulos et al., 2009).  
This suggests that targeting the graft, as a source of infection, with 
antimicrobials would be an efficient way to reduce post-operative infection 
rates.   
Vancomycin is a glycopeptide antibiotic originally introduced to treat Methicillin 
resistant Staphylococcus aureus (MRSA) and coagulase negative Staphylococcal 
species with proven bactericidal activity.  The minimum inhibition concentration 
required for Staphylococcus aureus is 0.5µg/ml, and ranges from 0.25µg/ml to 
2.0µg/ml for other bacteria(Andrews, 2002).  It is widely used in many forms in 
orthopaedic surgery; bone cement in routine arthroplasty, IV infusion to treat 
prosthetic joint infection and topical powder on spinal surgery wounds with 
results showing that it reduces infection significantly(Lemans et al., 2019; 
Nowinski et al., 2012).  A number of other surgical specialties utilise antibiotics 
and antimicrobials either topically on wounds or in solution to immerse and wrap 
implants prior to surgery, reporting significant reductions in 
infection(Dhabuwala, 2010; Tarakji et al., 2016; Vander Salm et al., 1989).  
Cardiothoracic surgery has been at the forefront of this, applying vancomycin 
powder to sternotomy wounds following results of a seminal paper in 
1989(Vander Salm et al., 1989) and now implanting cardiac electronic devices 
enveloped in a degradable antimicrobial sleeve(Tarakji et al., 2016).   
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The specific practice of wrapping the donor graft in a vancomycin soaked sterile 
swab prior to insertion in ACLR surgery has steadily increased since 2012 when 
the ‘vancomycin wrap’ was first described(Vertullo et al., 2012).  Since then, 
there have been a number of published studies and reviews which demonstrate 
significantly reduced post-operative infection rates in ACLR(Figueroa et al., 
2019; Jefferies et al., 2019; Pérez-Prieto et al., 2016; Phegan et al., 2016; 
Vertullo et al., 2012).         
The molecular effects of vancomycin on human and animal peri-articular tissues, 
including tendon has a limited evidence base.  Porcine chondrocyte death was 
significantly increased after exposure to vancomycin at doses of 5mg/ml or 
higher(Shaw et al., 2018).  Human in vitro studies have shown vancomycin 
toxicity to chondrocyte and osteoblast like cells, via a reduction in cell DNA, at 
doses of 250µg/ml and 125µg/ml for osteoblast and chondrocytes respectively, 
following 48hours of treatment(Antoci et al., 2007).  Two further studies have 
concluded that vancomycin is not toxic at doses up to 16µg/ml for 36 hours in an 
ex vivo chondrocyte model(Dogan et al., 2016) and up to 1000µg/ml for 72 hours 
in an in vitro osteoblast model(Edin et al., 1996).  Porcine tendon models show 
that vancomycin is effective at eliminating bacterial contamination at 5mg/ml 
after 20 minutes of soaking, and has no effect on the biomechanical properties 
at doses up to 10mg/ml(Schüttler et al., 2019).  Bovine studies have 
demonstrated that tendon can act as a reservoir for vancomycin, releasing the 
antibiotic for up to 24 hours into the joint, changing a source of infection, into 
an intra-articular prophylactic vehicle(Grayson et al., 2011).     
 Aims & Hypothesis 
The current work aimed to establish whether treatment with vancomycin at 
5mg/ml, the clinically used concentration, altered the structural or molecular 
function of the hamstring graft in anterior cruciate ligament reconstruction using 
human tendon in in vitro and ex vivo models.  Based on published animal models 
of the vancomycin wrap (Schüttler et al., 2019), it was hypothesised that 
vancomycin at 5mg /ml would have no detrimental molecular effects on the 




4.3.1 Cell viability  
MTT assay, described in section 2.5 was carried out with vancomycin in both 
0.9% saline and RPMI diluents, at 5mg/ml and 10mg/ml concentrations, over a 
time course of 30, 60 and 120 minutes. 
4.3.2 Apoptosis 
Induction of apoptotic pathways was analysed in tendon ex vivo by qPCR for 
apoptotic gene expression, method described in section 2.7, by ELISA for 
cytochrome C and caspase 3 protein quantitation, method described in section 
2.6 and by IHC staining for caspase 3, method described in section 2.4.  Caspase 
3 stained tissue sections were imaged under a light microscope (Olympus, DP22) 
at x10 and x40 magnification and compared with Isotype controls.  
Quantification of staining was performed in two stages.  Firstly, semi-
quantitative staging was performed on 5 random high-powered fields, grading 
the percentage of positively stained cells in that filed using the Modified Bonar 
Score: Grade 0, no staining; grade 1,1% to 10% of cells stained positive; grade 2, 
10% to 20% of cells stained positive; grade 3, more than 20% of cells stained 
positive).  Secondly, the total number of positive and negatively stained cells in 
each of the 5 high-powered fields was counted to generate the mean percent 
positive for stained cells. 
4.3.3 Matrix and Inflammation  
Changes to tendon matrix and inflammatory profile as a result of vancomycin 
was examined by qPCR, as described in section 2.7 and ELISA, as described in 
section 2.6 for inflammatory and matrix gene expression and protein 
quantitation respectively.  
4.3.4 Clinical data 
Clinical data on all ACL reconstructions was collected as described in methods 
section 2.1 with 6-month post-operative follow up to assess for infection, re-
operation or graft failure. 
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 Results  
4.4.1  Vancomycin and tenocyte viability 
The viability of tenocytes following treatment with vancomycin in RPMI diluent is 
shown in Figure 4-1.  At the clinically used concentration of 5mg/ml, tenocytes 
show reduced viability at all time points – 30, 60 and 120 minutes, however, this 
was only significant at the 60 minute time point (p<0.05).  At the higher 
concentration of 10mg/ml there is no significant reduction in tenocyte viability.  
At this higher concentration, the results may be due to saturation, as Figure 4-2 
shows the vancomycin crystallised and not all dissolved.  No further experiments 
using the 10mg/ml were conducted as this crystallization may affect results.  
The MTT assay was also assessed with vancomycin in a 0.9% saline diluent, 
however, the tenocytes showed cell death with both saline alone and with 
vancomycin after 30 minutes of treatment Figure 4-2.  The pH of these solutions 
was assessed and is shown in Table 4-1.  The acidity of 0.9% saline is thought to 
















Figure 4-1 MTT assay tenocyte viability 
Tenocyte viability following treatment with vancomycin in RPMI at varying concentrations at 30, 60 
and 120 minutes.  100% represents untreated control cells. Results are mean ± SEM, 5mg/ml N=6, 



























Figure 4-2 Images of treated tenocytes for MTT assay 
(A) Vancomycin 10mg/ml in RPMI diluent, showing the crystals that form at the higher dose. (B) 
Tenocytes treated with 0.9% saline for 30 minutes and (C) Tenocytes treated with vancomycin 
5mg/ml in 0.9% saline for 30 minutes, both showing that the cells have died. (D) Tenocytes treated 
with vancomycin 5mg/ml in RPMI.
A B C D 
200µm 200µm 200µm 200µm 
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Table 4-1 pH of vancomycin in solution 
Vancomycin maintains neutral pH in RPMI diluent at 5 and 10mg/ml.  Dissolved in acidic 0.9% 
saline, it reduces the pH further.  RPMI = Roswell Park Memorial Institute 1640 Medium. PBS = 
Phosphate buffered saline    
 Vancomcyin mg/ml 
 0 5 10 
RPMI 7.5 7.46 7.42 
PBS 7.4   
0.9% saline 5.5 3.75 3.63 
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4.4.2  Vancomycin and tendon apoptosis  
The expression of nine apoptotic genes, following vancomycin treatment of 
tendon explant in RPMI and 0.9% saline diluent is shown in Figure 4-3.  Tendon 
cultured in RPMI and 0.9% saline showed a trend towards increased expression of 
apoptotic genes when compared with fresh untreated tendon, however this was 
not significant.  There was also no significant difference in apoptotic gene 
expression seen between tendon cultured in RPMI vs 0.9% saline.  This finding is 
important, as RPMI is a laboratory solution used for cell and tissue culture and is 
not used or available in clinical practice.  Furthermore, the data shows that 
there is no significant difference in apoptotic gene expression between 0.9% 
saline, the current standard in clinical practice, and vancomycin in 0.9% saline.  
BAX and AIFM 1 show significant increased expression in vancomycin 0.9% saline 
compared to RPMI control.  BAX is a pro-apoptotic gene which results in 
cytochrome c release from mitochondria whilst AIFM1 is part of the caspase 
dependent apoptotic pathway.   
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Figure 4-3 Apoptotic gene expression in control and vancomycin treated tendon 
Apoptotic gene expression in control and treated tendon explants.  AIFM1, BAX, TNFr, caspase 3, 
FADD, FAS, FAS ligand, survivin, BCL2 gene expression in tendon explant at 16 hours following 1 
hour vancomycin treatment.  Data are mean ±SEM, normalised to untreated tendon, relative to 
housekeeping gene, N=5.  Analysis via ANOVA on ΔCT values, multiple comparisons: untreated vs 
RPMI, untreated vs saline, RPMI vs saline, saline vs vancomycin saline, RPMI vs vancomycin 
saline.   
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The effect on apoptosis was further explored by caspase 3 and cytochrome C 
protein quantitation in treated and control tendon explant tissue and 
supernatants.  Cytochrome C is mitochondrial signalling protein involved in the 
intrinsic apoptotic pathway (Garrido et al., 2006).  Figure 4-4 shows the results 
of Cytochrome C quantitation in 1-hour and 16-hour supernatants.  Saline and 
vancomycin saline treatment conditions are associated with a trend towards 
increased protein levels in supernatant, consistent with the BAX gene expression 
data, however, the results are not significant compared with RPMI control.  
There was no significant difference between saline alone and following the 
addition of vancomycin.           
Caspase 3, an enzyme common to both intrinsic and extrinsic apoptotic pathways 
was measured in supernatants by luminescence assay and by 
immunohistochemistry staining of tendon tissue.  Protein levels measured in 
tendon explant supernatant at 1-hour show reduced levels in both vancomycin 
treatment conditions compared with RPMI control and 0.9% saline alone.  At 16 
hours post treatment, caspase 3 protein levels increased in all conditions and 
there remained a trend towards reduced levels in supernatants from vancomycin 
saline treated tendon Figure 4-5.  At the 1-hour time point, there may have been 
interference in the assay by vancomycin, as both conditions showed low results.  
At 16 hours this would not be expected as the vancomycin solution is replaced 
with RPMI; these results concur with previously presented gene expression data 













Figure 4-4 Cytochrome C in control and treated tendon supernatants 
Tendon treated with vancomycin 5mg/m in RPMI or saline diluent for 1 hour.  Cytochrome C 
measured in 1 hour and 16 hour supernatants. Data are mean ± SEM, N=3.  Analysis via ANOVA, 




Figure 4-5 Caspase 3 in control and treated tendon supernatants 
Tendon treated with vancomycin 5mg/m in RPMI or saline diluent for 1 hour.  Caspase 3 measured 
by luminescence assay in 1-hour and 16-hour supernatants. Data are mean ± SEM, N=6 for 1 
hour, N=3 for 16-hour.  Analysis via ANOVA, multiple comparisons: RPMI vs saline, RPMI vs 




Caspase 3 antigen immunohistochemistry staining results are shown in Figure 
4-6.  The results show that treatment with vancomycin does not cause disruption 
to the uniform collagen tendon structure, however, it is associated with a trend 
towards more positive staining for caspase 3 compared with untreated or control 
tissue in RPMI and 0.9% saline.  Images from two different donors are shown in 
Figure 4-6C and show the variability in clinical samples.  Donor 1977 has areas of 
increased cellularity, vascularity and loss of polarisation of collages fibres across 
control and treated tendon.  These features are in keeping with pre-existing 




















Figure 4-6 Caspase 3 Immunohistochemistry staining of control and treated tendon explant 
(A) Graph illustrating modified Bonar scores from tendon explant tissue stained for cleaved 
caspase 3, N=5.  Modified Bonar score depicts number of positively stained cells per 5 high-
powered field (x40) per sample, 0=no staining, 1=1-10%, 2=10-20%, 3>20%, mean +/- SEM, 
analysis by ANOVA, multiple comparisons: RPMI vs saline, RPMI vs vancomycin saline, saline vs 
vancomycin saline.  (B) Quantitative expression of caspase 3, mean % cells positive per treatment 
condition based on 5 high-power fields, N=5, analysis by ANOVA, multiple comparisons untreated 
vs RPMI/saline, RPMI vs saline, RPMI vs vancomycin saline, saline vs vancomycin saline. (C) 
Caspase 3 IHC staining of human tendon explant, treated with experimental conditions for 1 hour, 
isotype rabbit IgG bottom left corner.  Two donors represented 2281 and 1977, x10 and x40 
magnification. 
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4.4.3 Vancomycin and tendon matrix 
Tendon matrix gene expression results are shown in Figure 4-7.  There was no 
significant difference in RPMI, 0.9% saline or vancomycin treated tendon 
compared with fresh untreated tendon.  Additionally, vancomycin treated 
tendon showed no significant increase in matrix gene expression compared with 
the laboratory control RPMI or clinical control 0.9% saline, however, it was 
associated with a trend towards increased expression of collagen 3α.  This 
protein is associated with tendon damage and may be a reflection of explant 
model preparation as described in methods, or evidence of pre-existing 
tendinopathy in clinical samples.  Quantitation of collagen 1α in tendon explant 
supernatants showed a non-significant trend towards reduced protein in saline 
and vancomycin saline treated tendon.
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Figure 4-7 Tendon matrix gene and protein expression in control and vancomycin treated 
tendon 
Vancomycin effect on matrix gene and protein expression in tendon.  Collagen 1α, Collagen 3α, 
Decorin and Tenascin C gene expression in tendon explant at 16 hours following 1 hour 
vancomycin treatment.  Data are mean ±SEM, normalised to untreated tendon, relative to 
housekeeping gene, N=5, analysis by ANOVA, multiple untreated vs RPMI, untreated vs saline, 
RPMI vs saline, saline vs vancomycin saline, RPMI vs vancomycin saline.  Collagen 1α protein 
measured by quantitative ELISA assay.  Tendon treated for 1 hour, incubated for 16 hours, data 
represent mean ±SEM, N=10.  Analysis via ANOVA, multiple comparisons: RPMI vs saline, saline 
vs vancomycin saline, RPMI vs vancomycin saline.
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4.4.4 Vancomycin and tendon inflammation  
Tendon inflammatory gene expression and cytokine results are shown in Figure 
4-8.  There are significant increased gene expression values for IL-6 and MMP3 in 
RPMI vs untreated tendon and for IL-8 gene expression for saline treated vs 
untreated tendon.  This shows that culturing tendon ex vivo, even in RPMI can 
lead to an inflammatory profile within the tissue.  From multiple comparison 
analysis, there were no significant increases in tendon inflammatory cytokine 
gene expression when saline and vancomycin in saline were compared with RPMI.  
Although not significant, the cytokine data demonstrate a consistent trend 
towards reduced inflammatory protein release with vancomycin in saline 




Figure 4-8 Tendon inflammatory gene and protein expression in control and vancomycin 
treated tendon 
The effect of vancomycin on inflammatory gene and protein expression in tendon. IL-6, IL-8, 
MMP3, CCL2 and HMBG1 gene expression in tendon explant at 16 hours following 1 hour 
vancomycin treatment.  Data are mean ±SEM, normalised to untreated tendon, relative to 
housekeeping gene, N=5, *p<0.05 **p<0.01 relative to untreated tendon.  IL6, IL8, MMP3 and 
CCL2 protein measured by quantitative ELISA assay.  Tendon treated for 1 hour, incubated for 16 
hours, data represent mean ±SEM, IL6, MMP3, CCL2 N=11, IL8 N=10, analysis via ANOVA, 
multiple comparisons: untreated vs RPMI, untreated vs saline, RPMI vs saline, saline vs 





4.4.5 Vancomycin and tendon biomechanics 
Tendon explant was collected and cut into 3cm sections, as described in 
methods section 2.3.1.  Due to the process involved in biomechanical analysis, a 
minimum size of 2.5cm of tendon was required for each treatment condition, 
therefore, due to sample availability only 0.9% saline and vancomycin 5mg/ml in 
saline were assessed, as these are the clinically relevant conditions.  N=5 donors 
have been treated with experimental conditions and stored at -20oC.  These 
samples were unable to be analysed in the time period due to restrictions in 
place following the Covid-19 pandemic.  
4.4.6 Vancomycin wrap clinical data 
Over a 12-month period there were 142 ACL reconstructions performed, in 38 of 
these the use of vancomycin wrap was documented on the operation notes, data 
presented in Table 4-2.  All patients in both treatment groups received 
prophylactic antibiotics in accordance with hospital protocol and there were no 
significant differences in patient age, ASA grade or type of graft used.  There 
was one documented case of septic arthritis in the vancomycin wrap group and 
five other cases of superficial wound infection, two in the vancomycin wrap 
group.  The deep infection case was a hamstring ACL graft, ASA grade 1 patient.  
The infection started with breakdown of the tibial wound and development of a 
sinus.  Theatre tissue samples grew MSSA and E.coli.  The patient was treated 
with surgical washout & debridement, plastic surgery input for rotational flap to 
cover the tibial skin defect and an extended course of antibiotics.  The 
prosthetic endobutton securing the graft was removed at debridement, with 
subsequent follow up lachmans test was documented as having a firm endpoint.  
Of the five documented superficial wound infections, two required surgical 
washout, both documented as not communicating with the joint.  All required 
oral antibiotics for duration of 1-2 weeks.  There was no significant difference in 
infection rates between the two treatment groups.  There were no documented 
graft failures at 6 months follow up.  
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Table 4-2 Clinical data from ACL reconstructions 
All ACL reconstructions undertaken in a 12-month period July 2018-July 2019 in a single centre, 
operating across two clinical sites. Follow up at 6 months for details of infection.  Analysis by 






Number of patients 38 104  
Prophylactic antibiotics % 100 100  
Age, mean (range) 29.7 (19-49) 26.8 (13-56) 0.62 






















Infection: 6 month follow up 
• Septic arthritis 








 Discussion  
The first description of the “vancomycin wrap” for ACLR was in 2012; since then 
a number of studies have demonstrated its effectiveness in combination with 
usual IV antibiotic prophylaxis at reducing post-operative infection rates to 
almost 0%(Baron et al., 2019; Figueroa et al., 2019; Jefferies et al., 2019; 
Offerhaus et al., 2019; Pérez-Prieto et al., 2016; Phegan et al., 2016; Vertullo et 
al., 2012).  One study reported infection rates in the control group, treated with 
prophylactic IV antibiotics alone as 1.4% (N=285) compared to 0% in patients who 
were treated with prophylactic IV antibiotics in combination with vancomycin 
wrap (N=870)(Vertullo et al., 2012).  A further study which conducted post-
operative follow up of 1300 consecutive ACL reconstructions using the 
vancomycin wrap in combination with standard IV antibiotic prophylaxis, 
reported zero post-operative infections against a retrospective control group 
(N=240) who reported infections in 2.4% of patients(Phegan et al., 2016).  A 
more recent study which looked at 1640 patients, found the use of vancomycin 
wrap during ACL reconstruction was associated with a 10-fold reduction in post-
operative infection (0.1% vs 1.2%)(Baron et al., 2019).   
This work is the first to evaluate the molecular and structural effects that 
vancomycin has on a human hamstring graft for ACLR. The results of the current 
work indicate that vancomycin appears safe and has no detrimental effects on 
the cellular or molecular structure of the tendon graft used for ACLR.   
The addition of vancomycin at the commonly used clinical dose of 5mg/ml did 
result in a reduction in tenocyte viability at 60 minutes.  It is common in an in 
vitro model to experience biological variability and we did not see this reduction 
sustained following 30 or 120 minutes of treatment Figure 4-1.  Previously 
published literature that used the same assay to assess chondrocyte viability 
found vancomycin safe at doses up to 16µg/ml over 36hours of treatment, which 
is above the minimum inhibitory concentration for staphylococcus aureus, the 
most commonly culture pathogen in ACLR infection (Dogan et al., 2016).  At 
higher doses of 10mg/ml, the antibiotic crystallised in solution Figure 4-2. This 
dose was therefore no longer used as it could interfere with results and is not 
used in clinical practice.  
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There were many variables to consider when setting up the tendon explant 
model, which was used for apoptotic, matrix, inflammatory and biomechanical 
analysis.  It remains unclear from published literature how much of the 
antibiotic is absorbed both by the sterile swab and by the tendon itself and 
therefore what concentration the tenocytes are exposed to.  In one study it is 
reported that the sterile swab absorbed on average 7ml of the 100ml solution 
containing vancomycin at 5mg/ml(Vertullo et al., 2012).  Bovine studies 
specifically looking at absorbance and elution of vancomycin from tendon have 
demonstrated that both of these characteristics are affected by graft size and 
rinsing(Grayson et al., 2011), which occurs in clinical practice once implanted, 
with arthroscopic washout of the joint.  It is challenging to develop a model that 
accounts for all of these variables.  We therefore submerged uniform size tendon 
explant pieces in vancomycin or saline for 1 hour.  This eliminated any effect 
drying may have had on the tendon and was long enough to encompass reported 
average times from graft harvest to implantation, 30 minutes (range 28 - 43 
minutes)(M E Hantes et al., 2008).  The graft was washed twice with RPMI and 
then cultured for 16 hours post 1 hour treatment.  We used this as our ‘surgical 
scenario’ model and feel this accurately reflects current practice and gives 
confidence that our molecular findings translate to everyday clinical practice.  
Changes in gene expression and protein release into supernatant are not instant 
reactions therefore, allowing 16 hours of tissue culture ensured our results 
reflected changes in the tendon molecular environment.  Washing of the tendon 
following treatment was employed which replicates clinical practice and studies 
show that after 12 hours, elution rates between rinsed and un-rinsed tendon are 
no longer significantly different and have both reached a steady state(Grayson 
et al., 2011).  
Tendon explant cultured in RPMI showed a small increase in apoptotic gene 
expression compared with fresh untreated tendon, however this was not 
significant.  Clinically relevant was the finding that tendon cultured in 0.9% 
saline showed no significant difference compared with both fresh untreated 
tendon and tendon cultured in RPMI.  RPMI is deemed ideal culture media, it is 
not available in clinical practice, therefore 0.9% saline was used as the clinical 
control.  Prior to the introduction of the vancomycin wrap and in centres that do 
not use this practice, the ACL graft is wrapped in 0.9% saline.  There was a 
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consistent trend towards increased apoptotic gene expression in all conditions 
(saline, vancomycin RPMI and vancomycin saline) compared with RPMI alone, 
however, the results were only significant for two apoptotic genes, BAX and 
AIFM1, when vancomycin saline was compared to RPMI Figure 4-3.  BAX and 
AIFM1, associated with the cytochrome C and caspase 3 apoptotic pathways.  
Cytochrome C protein data at 1 and 16 hours concur with the BAX gene 
expression data, showing a trend towards increased levels with vancomycin 
saline, however, the protein release was not significantly different to control 
RPMI Figure 4-4.  Caspase 3 protein data analysed by luminescence assay at 1 
hour showed potentially spurious results, with marked reductions in caspase 3 in 
both vancomycin treatment groups Figure 4-5.  The 1 hour supernatant contains 
dissolved vancomycin, it is possible the antibiotic may interfere with the 
luminesce readings.  At 16 hours, following incubation with RPMI alone, this was 
not the case and the results are in line with gene expression data, showing a 
slight trend towards reduction in caspase 3 with vancomycin in saline. 
Further caspase 3 analysis was performed with IHC staining.  The representative 
images form donor 2281 show that vancomycin treatment caused no disruption 
to the uniform tendon structure Figure 4-6C.  The semi quantitative scoring 
shows that there was a trend towards more positive staining with vancomycin 
treatment, however, this was not significant when compared with untreated or 
control tendon. Images from donor 1977 highlight the variability in clinical 
samples.  The images show tendon with areas of increased cellularity, 
vascularity and loss of polarisation of collages fibres across both control and 
treated tendon.  These findings are in keeping with tendinopathy and are not 
thought to be caused by tendon culture or vancomycin treatment(Fearon et al., 
2014).   
Exploration of the effect of vancomycin treatment on the matrix component of 
the graft post treatment demonstrated no significant difference in matrix gene 
expression compared to untreated tendon, control RPMI treated tendon, or 
tendon in saline alone.  Vancomycin in saline was associated with an increase in 
collagen 3α gene expression, although not significant.  This result comes from 
one outlier.  As seen with the immunohistochemistry images in Figure 4-6C, this 
may reflect pre-existing tendinopathy changes in that donor tendon and 
highlights the issue of variability in clinical samples.  The results show a 
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reduction in Collagen 1α protein release in vancomycin saline treated tendon 
supernatants compared with all 3 other treatment conditions.  This finding may 
be as a result of lower Collagen 1α protein breakdown from the tissue explant 
into the supernatant following vancomycin treatment and thus may reflect a 
positive effect of vancomycin treatment. 
The primary functions of the tendon graft in ALCR are transfer mechanical load 
and mechanical stability.  Although the current study did not directly measure 
the biomechanical properties of the tendon graft following vancomycin 
treatment, histological data indicates vancomycin treatment does not affect the 
integrity of the graft structure.  This is further inferred by the matrix gene and 
protein results noted above.  The preparation of samples for biomechanical 
analysis has been completed and it is hoped that this work can be finalised in 
the coming months.  Recent published literature has evaluated the 
biomechanical properties of bovine patella tendon following saline and 
vancomycin 5mg/ml in saline treatment.  The results showed no difference in 
Young’s modulus or elongation strain between the treatment groups concluding 
that vancomycin at 5mg/ml did not alter the material properties of the 
tendon(Lamplot et al., 2021).   
Vancomycin, as well as being antimicrobial has also been shown to have immune 
modulating potential.  In inflammatory mediated conditions, it has been shown 
to act via alterations in the host T cell population which leads to reduced 
inflammation(Abarbanel et al., 2013).  In a sepsis model however, vancomycin 
was found to have pro-inflammatory effects on the innate immune system(Bode 
et al., 2015).  We therefore investigated the inflammatory effect vancomycin 
had on tendon.  Our results show that vancomycin in saline showed a consistent 
trend towards reduced inflammatory cytokine release, compared with 0.9% 
saline and RPMI alone and vancomycin in RPMI diluent.  Previous work has shown 
that inflammation has a negative effect on the health of a tendon and IL-6 is 
involved in the development of tendinopathy(Millar et al., 2009).   
These results suggest vancomycin treatment is not detrimental to the cellular 
viability of the tendon graft but may have small beneficial effects pointing 
towards a homeostatic, molecular environment to encourage graft viability.  The 
reduction in collagen 1α release and inflammatory cytokine release indicate 
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reduced cellular stress and may be linked with the reduction seen in apoptotic 
gene expression of caspase.  A recent retrospective cohort study reviewed 1779 
patients who underwent ACLR, with vancomycin soaking of the hamstring graft 
employed in 853 of these cases.  Over a 5 year period, whereby 100 patients 
were randomly selected for follow-up each year, graft failure and re-rupture 
rates were reported to be significant lower in the vancomycin wrap group; 8 
failures out of 257 vs 16 failures out of 167 patients in the control group 
p<0.01(Offerhaus et al., 2019). 
The clinical data presented in this study represents small numbers from a single 
unit covering two hospital sites.  Using the operation note to establish the use of 
the vancomycin wrap may underestimate the numbers in this group as there is 
no option to select “vancomycin 5mg/ml wrap’ from the pre-populated choices 
on the currently used software programme.  The one deep infection with MSSA 
and E.coli was from a patient who received a vancomycin wrap, and whilst 
vancomycin is active against these pathogens, it is not the first line choice for 
E.coli.  Risk factors and prevention strategies for post-operative infection in 
ACLR are multifactorial, with longer surgical times and higher BMI both shown to 
be independent predictors(Baron et al., 2019).  When infection rates are already 
low, one intervention alone may not consistently alter outcomes.  This was the 
conclusion in one study assessing the efficacy of local vancomycin to spinal 
surgery wounds who reported no difference in infection rates vs usual IV 
antibiotic prophylaxis (1.61% vs 1.68%)(Tubaki et al., 2013).  Furthermore, 
infection in ACLR can be caused by multiple pathogens, which may not be 
susceptible to vancomycin and the increasing use of one antibiotic as local 
prophylaxis may begin to select out for non-staphylococcal infections, which 
doesn’t constitute resistance, but may have implications for clinical treatment 
protocols should infection occur (Heller et al., 2015).   
Antibiotic resistance is an important consideration as an increasing number of 
antibiotics are being used in the peri-operative period as prophylaxis.  Data from 
cardiothoracic surgery, using vancomycin paste in sternotomy wounds has not 
found antibiotic resistance to be an issue given that topical use does not lead to 
therapeutic serum levels of the drug(Lazar et al., 2011).  Animal studies have 
demonstrated that once wrapped in a vancomycin solution, the ACL graft can act 
as a reservoir, continuing to release the drug over 24 hours, at gradually 
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decreasing levels, below a dose considered toxic to cells(Grayson et al., 2011).  
Exposing tissues to prolonged subtherapeutic levels of a drug is a known way to 
establish resistance(Andersson & Hughes, 2014).  Future evaluation on the safety 
of the vancomycin wrap in ACLR could include serum and synovial drugs levels 
following surgery to investigate this. 
There are limitations to this work, primarily with the tendon explant model.  
There are many variables involved in the vancomycin wrap during surgery, the 
volume of antibiotic absorbed by the swab and by the graft, both influenced by 
the volume of tissue and rinsing during the arthroscopic procedure and the 
effect of drying of the graft prior to implantation, under the lamina flow.  It is 
challenging to create a model that encompasses all of these variables.  We 
believe the model we used accurately reflects the effect of the antibiotic alone 
on the graft.  Further ex vivo work and clinical follow up are recommended to 
investigate the biomechanical properties of human tendon graft post treatment, 
if there is any association with reduced graft failure and any indications of 
antibiotic resistance.  
 Summary and future work 
 
Figure 5-1 Summary of findings from Chapter 3 
A diagram summarising the key finding from the sequencing of tissue and blood from orthopaedic 
revision surgery using an immune gene response panel.  Tissue sequencing results demonstrated 
transcriptional signatures which allowed discrimination between aseptic, chronic and acute 
infection.  Furthermore, metagenomic signatures highlighted the similarity between the immune 
signature form chronic infection and aseptic control tissue, indicating an attenuated immune 
response seem with chronic infection, potentially due to bacteria embedded in biofilm matrix.  
Blood sequencing results demonstrated a unique transcriptional signature that identified 
staphylococcal from streptococcal infection.     
 Gene expression signature from PJI tissue 
Synovial tissue was collected from patients undergoing orthopaedic revision 
arthroplasty.  This tissue was fixed in formalin and sections were analysed for 
gene expression using a 2002 immune response gene panel.  This work represents 
the first time the immune gene response panel, developed by HTG molecular, 
has been analysed on PJI and aseptic tissue from orthopaedic revision 
arthroplasty patients.  It is also the first sequencing work to investigate the host 
immune response as a potential diagnostic test in PJI.  The data showed that 
status – aseptic, acute or chronic infection had the largest effect on the gene 
sequencing results from synovial tissue.  Tissue from the PJI cohort had 
significantly higher expression of genes involved in immune ‘cell chemotaxis’ 
and ‘response to a molecule of bacterial origin’ which are clinically relevant 
pathways in infection.  Further analysis of the data allowed us to develop 
AUC/ROC curves to assess the diagnostic ability of the immune response gene 
panel and use machine learning to optimise a 4 gene panel for PJI: G0S2, CXCL5, 
NR1D2 and DBP, with sensitivity and specificity of 82% and 100%% respectively.  
In addition, data analysis identified sub-groups within the PJI cohort relating to 
time frame of infection, those cases deemed as ‘acute’ infection as per MSIS 
2018 guidelines showed a different pattern of gene expression to ‘chronic’ 
infection and aseptic control.  We concluded that the PJI transcriptomic 
response was largely driven by the ‘acute’ infection cohort, with the chronic 
infection cohort sharing a gene expression pattern with aseptic control Figure 
5-1.  From this we inferred that the immune response in chronic implant related 
infection is attenuated, linking with known biofilm biology, where bacteria are 
shielded from the immune system.  This may have implications for the use of 
known and future immune mediated biomarkers including alpha defensin and 
leucocyte esterase in chronic PJI diagnosis.   
 Gene expression signature from PJI blood 
Peripheral blood was collected preoperatively from patients undergoing 
orthopaedic revision arthroplasty for gene expression analysis on a 2002 gene 
immune response panel.  This work represents the first time the immune gene 
panel developed by HTG molecular, has been analysed in blood using a revision 
arthroplasty cohort – including PJI and aseptic cases.  Furthermore, this work is 
136 
 
novel in its evaluation of the immune repose as a potential diagnostic test in PJI.  
Variance partition analysis showed that bacterial strain was a factor that had 
one of the biggest effects on sequencing results.  Annotating blood samples by 
bacterial strain identified a significant difference in immune gene signature 
between Staphylococcal and Streptococcal infections.  The current diagnostic 
algorithms rely on microbiological tissue or fluid analysis for bacterial 
identification and diagnosis, however, as previously noted, identification of 
tissue planes can be unreliable in revision surgery and may miss areas of 
infection and biofilm clusters.  Blood is a more uniform biological sample, 
avoiding the need for surgery to obtain sterile peri-articular samples.  
Identification of bacterial infection from blood is an area of evolving research, 
particularly in paediatric infection and respiratory medicine. 
 Limitations of PJI sequencing work  
This was a pilot study to demonstrate the use of a novel sequencing technology.  
The numbers of patients included (n=24) was low and sequencing data was not 
able to be generated for n=1 patient in the tissue analysis due to low sample 
quality and n=4 in the blood analysis due to insufficient library concentration for 
sequencing.   
During revision arthroplasty surgery, defining specific tissue planes/orientation 
can be challenging, therefore, there was wide variability in the tissue samples 
received.  Furthermore, sequencing analysis was performed on one 5µm section 
of tissue from each patient, previous literature has noted variation in spatial 
distribution of bacteria in PJI (Walker et al., 2020).  Both factors may have 
affected tissue sequencing results.  Insufficient library concentration from n=4 
blood samples may have been the result of inadequate mixing with the 
stabilising agent at the time of sample collection, or an issue with binding of the 
DNA nuclease protection probes/wingmen to the target RNA, meaning target 
RNA was digested by the S1 nuclease.  Gene expression analysis was available for 
two bacterial strains Staphylococcal and Streptococcal.  In PJI multiple 
pathogens are commonly involved, in some cases polymicrobial infection.  This 
pilot study didn’t include polymicrobial infections with different bacterial genus 
strains, however, did include multiple species eg: streptococcus mitis/oralis 
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grouped as ‘Streptococcal’.  Due to COVID-19 planned validation of the gene 
signature in synovial tissue and blood could not be carried out.         
 PJI sequencing future work 
Laboratory and larger patient cohort validation of the results from this pilot 
study are now required.  The identification of a gene signature that identifies 
Staphylococcal versus Streptococcal in blood is an encouraging finding for PJI 
diagnosis in the future, as it would allow gene level information without the 
need for extended microbiological tissue culture.  A larger cohort will also 
identify more bacterial strains and assess if they too produce a unique immune 
signature.  Next generation gene sequencing techniques are now routinely being 
evaluated in research focusing on PJI.  Common pitfalls with regards to human 
DNA contamination of the sample are reported.  This pilot study reports the use 
of a novel sequencing technique switching the diagnostic method – instead 
looking for the host immune repose to a pathogen.  These sequencing methods 
have the potential to take PJI diagnosis into the era of personalise medicine.
 
Figure 5-2 Summary of findings from Chapter 4 
A diagram summarising the main findings from the working assessing the molecular effects of 
vancomycin on tendon.    Apoptosis: In vitro work demonstrated a reduction in tenocyte viability 
following treatment of cells with vancomycin at 60 minutes.  This reduction was not seen at the 30- 
or 120-minute time point and could therefore represent biological variability in the assay.  It is 
unclear how much of the vancomycin the tenocytes are directly exposed to.  Therefore, further 
apoptosis assays used the tendon explant model and showed no significant or consistent increase 
in Caspase 3 protein, suggesting vancomycin did not induce tenocyte apoptosis.  Matrix: After 
treatment with vancomycin in the tendon explant model, gene expression of collagen1a and 
collagen3a  were not significantly increased indicating no aberrant change to tendon matrix 
composition.  Inflammation: Vancomycin treatment in the tendon explant model was associated 
with a trend towards reduced inflammatory cytokine release which may represent a role for 
vancomycin inducing a homeostatic molecular environment  and could be implicated in the 
increased graft survival seen in clinical practice (Offerhaus et al., 2019) .
 Molecular effects of vancomycin in vitro 
Tenocytes were cultured from surplus human hamstring tendon following ACLR 
and used to assess cell viability following treatment with vancomycin antibiotic.  
We found a reduced tenocyte viability after 60 minutes, however this finding 
was not seen at 30 or 120 minutes.  This may be due to biological variability in 
the assay, however, all time points showed an overall trend towards reduced 
cell viability.  These experiments used 5mg/ml of vancomycin and as explained 
in the ex vivo model, variance in antibiotic absorbance along with interposition 
of matrix proteins make it challenging to know the concentration tenocytes in 
vivo are exposed to.  It is also unclear if a reduction in tenocyte viability 
translates into a clinical difference in outcomes following ACLR as the process of 
graft integration following ACL ‘ligamentisation’ is known to include a period of 
cell avascular necrosis.  
 Molecular effect of vancomycin ex vivo 
Surplus tendon tissue following surgery for ACLR was used to set up a tendon ex 
vivo model to investigate the molecular effect of vancomycin on human tendon.  
We found that treatment of the tendon with 5mg/ml of vancomycin solution up 
to 1 hour was not associated with a significant or consentient increase in the 
expression of apoptotic markers.  Gene expression of two apoptotic proteins 
AIFM 1 and BAX was increased following vancomycin treatment, however, 
protein analysis of the associated cytochrome C and caspase 3 pathways did not 
find a significant increase with vancomycin compared with control conditions.  
Vancomycin treatment was not found to significantly alter tendon matrix 
proteins but was associated with a significant reduction in the release of 
inflammatory cytokines.  Previous work has discussed the negative effect 
inflammation can have on tendon and the development of tendinopathy (Millar 
et al., 2009).   These findings suggest that vancomycin may have a homeostatic 
and beneficial effect on the health of the tendon graft.  In line with this finding, 
recent evidence has pointed towards prolonged graft integrity following ACLR 
with vancomycin treatment of the graft (Offerhaus et al., 2019).   
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 Limitations of tendon vancomycin work 
The in vitro tendon model used RPMI as the control solution, in clinical practice 
0.9% saline is used, however this lowered pH and altered the osmotic 
environment causing tenocyte cell death.  When whole tendon sections were 
used in the ex vivo model, 0.9% saline was able to be used at the control, 
suggesting a level of protection when the cells are embedded in matrix.    
Obtaining high quality human tendon samples from ACL surgery is challenging, 
defining when the sample was taken – before or after graft preparation is crucial 
as it may have already been affected by drying or damaged during stitching or 
passing through the bone tunnels.  However, using human tissue enabled better 
translation of laboratory results to clinical practice.  There were several 
challenges outlined in setting up the tendon ex vivo explant model including the 
volume of antibiotic absorbed by the graft influenced by the size of graft and 
rinsing during the arthroscopic procedure along with the effect of drying during 
graft preparation in the lamina flow theatre.  It was additionally challenging to 
create a model that considered all these variables to allow conclusions to be 
draw on vancomycin effect only.  We believe the model we established was 
consistent, with uniform size tendon sections being immersed in antibiotic 
solution, eliminating drying and therefore accurately reflecting the effects of 
vancomycin on tendon.      
 Vancomycin tendon future work 
Biomechanical analysis of ex vivo tendon treated with vancomycin was planned 
for this project with tendon tissue collected, treated and stored ready for 
analysis.  Due to COVID 19 these experiments could not be carried out.  Recent 
publications have shown that vancomycin has no detrimental effects on tendon 
biomechanical properties, however, these papers used animal tissue with bovine 
and porcine tendon models (Lamplot et al., 2021; Schüttler et al., 2019).  
Vancomycin treatment of the ACL grafts is becoming more common in clinical 
practice and it is important to establish the risks of antibiotic resistance.  It 
remains unclear how much, if any, of the vancomycin is absorbed into the 
systemic circulation following surgery.  This level should be established as 
repeated exposure of bacteria to subtherapeutic levels of an antibiotic is a 












 Appendix A 
Table 6-1 Studies evaluating Interleukin - 6 in Prosthetic Joint Infection 
Details of the studies which evaluated IL-6 as a biomarker for PJI in serum and synovial fluid.  
ELISA = Enzyme Linked Immunosorbent Assay.  





10 pg/ml Serum ELISA 100% 95% 
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Majors 2019 Aseptic 27 
PJI 32 
9.14pg/ml Serum ELISA 81% 63% 
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 Appendix B 
Table 6-2 Studies evaluating Multiplex PCR in Prosthetic joint infection 
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Table 6-3 Studies evaluating Multiplex Cartridge Systems in the diagnosis of Prosthetic joint 
Infection 
All studies evaluated the Unyvero i60 Implant and tissue infection ITI cartridge that includes 102 
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 Appendix C 
Ethical approval documentation for surplus tissue collection  
WoSRES 
West of Scotland Research Ethics Service   
 
Mrs Jane Hair 
NHSGGC Bio-repository 
GGC Bio-repository, Level 3 
Laboratory Medicine Building, 1345 Govan 
Road 







West of Scotland REC 4 






Date 14 March 2017 
Direct line 0141-232-1806 
e-mail Wosrec4@ggc.scot.nhs.uk 
 
Dear Mrs Hair 
 
Title of the Research Tissue Bank: NHSGGC Bio-repository and Pathology Tissue 
Resource II 
REC reference: 16/WS/0207 
Designated Individual:  
IRAS project ID: 199711 
 
Thank you for your letter of 10 February 2017, responding to the Committee’s request for further 
information on the above research tissue bank and submitting revised documentation. 
 
The further information was considered at the meeting of the Sub-Committee of the REC held 
on 14 March 2017.  A list of the members who were present at the meeting is attached. 
 
We plan to publish your research summary wording for the Research Tissue Bank on the HRA 
website, together with your contact details. Publication will be no earlier than three months from 
the date of this favourable opinion letter.  The expectation is that this information will be 
published for all Research Tissue Banks that receive an ethical opinion but should you wish to 
provide a substitute contact point, wish to make a request to defer, or require further 
information, please contact hra.studyregistration@nhs.net outlining the reasons for your 
request.Under very limited circumstances (e.g. for student research which has received an 
unfavourable opinion), it may be possible to grant an exemption to the publication of the 
Research Tissue Bank.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion of the above 
research tissue bank on the basis described in the application form and supporting 
documentation as revised. 
 
The Committee has also confirmed that the favourable ethical opinion applies to all research 
projects conducted in the UK using tissue or data supplied by the tissue bank, provided that the 
release of tissue or data complies with the attached conditions.  It will not be necessary for 
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Ms Clare Orange 
University of Glasgow-Institute of Infection, Immunity 
& Inflammation  
3rd Floor Laboratory Medicine Building 




West of Scotland REC 4 





Date 30 August 2019 
Direct line 0141 314 0214 
E-mail WoSREC4@ggc.scot.nhs.uk 
 
Dear Ms Orange 
 
Title of the Research Tissue Bank: NHS GG&C Additional Sample Tissue Resource 
to Support I3I Research-II 
REC reference: 19/WS/0111 
Designated Individual: Professor Iain B  McInnes 
IRAS project ID: 265704 
 
Thank you for your letter of 28 August 2019, responding to the Committee’s request for further 
information on the above research tissue bank and submitting revised documentation. 
 
The further information was considered at the meeting of the Sub-Committee of the REC held 
on 31 August 2019.  A list of the members who were present at the meeting is attached. 
 
We plan to publish your research summary wording for the Research Tissue Bank on the HRA 
website, together with your contact details. Publication will be no earlier than three months from 
the date of this favourable opinion letter.  The expectation is that this information will be 
published for all Research Tissue Banks that receive an ethical opinion but should you wish to 
provide a substitute contact point, wish to make a request to defer, or require further 
information, please contact hra.studyregistration@nhs.net outlining the reasons for your 
request.Under very limited circumstances (e.g. for student research which has received an 
unfavourable opinion), it may be possible to grant an exemption to the publication of the 
Research Tissue Bank.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion of the above 
research tissue bank on the basis described in the application form and supporting 
documentation as revised. 
 
The Committee has also confirmed that the favourable ethical opinion applies to all research 
projects conducted in the UK using tissue or data supplied by the tissue bank, provided that the 
release of tissue or data complies with the attached conditions.  It will not be necessary for 
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